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2'Sweet dreams are made of these 
Who am I to disagree
I travel the world and the seven seas 
Everybody's looking for something'
Sweet Dreams
Annie Lennox
I am the dark-avised, the widower, the inconsolable, 
The Prince of Aquitaine before his ruined tower:
My only star is dead; and now my jewel-studded lute 
Will only bear the blackened sun of Melancholia
My forehead is red yet with the kiss of the queen 
I have dreamed in the grotto where the siren swims 
And twice I have crossed the Acheron, triumphant ...
El Desdichado
Gerad de Nerval
'In my distress, well I wanted someone to blame me 
In my devastation.... I wanted so to change 
In my way..., disaster was the only thing that I
could depend on..
But it's alright,... I'm doing the best that I can'
S. Nicks
'She is my sun and ever she eclipses me, burning me with 
her fire. Yet before I go, for one time at least I 
shall outshine her ; supernova into oblivion, to end 
in darkness as it was begun.
Yet I cannot not love her for her spirit shines bright 
beyond belief for all to see. Yet ever it flames in 
my mind, slowly consuming me. She knows this not and 
I would never say. For she is my sun and no one wishes 
to live their life in perpetual darkness.1
D.G.H.
'Oh wad some power the giftie gie us 
To see oursels as ithers see usl 
It wad frae mony a blunder free us,
And foolish notion:
What airs in dress and gait wad lea'e us,
And even devotionl
To A Louse
Robert Burns
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SUMMARY
The herpes virus, herpes simplex type 1 (HSV-1) contains 
around 70 genes, most of which are expressed during lytic 
infection of BHK cells in culture. Two of the enzymes 
encoded by herpes simplex type 1 were studied using 
enzymatic, electrophoretic and immunological techniques.
The deoxyribonuclease
The deoxyribonuclease or DNase is encoded by gene UL12 
of herpes simplex type 1. The enzyme has both exo- 
and endonuclease activity and appears to be essential
for virus growth in cell culture. The function of the 
DNase during lytic infection is as yet unknown.
Modification of the DNase
Two dimensional gel electrophoresis and subsequent immuno­
blotting of the purified DNase showed a complex pattern 
made up of many spots which indicated that the protein 
was modified. The immunoblot pattern remained complex 
throughout the infection, although the distribution of 
protein between the spots varied and seemed to indicate 
a reduction in modification at late times in the infection. 
The effect of various phosphatases on the DNase indicated 
that at least part of the modification was due to phos­
phorylation of the enzyme. There may also be an element 
of ADP ribosylation but this remains unconfirmed.
Phosphorylation, jln vitro, of the DNase by various kinases 
showed that cAMP dependent protein kinase, protein kinase C, 
casein kinase II and the US3 protein kinase of HSV-1 could 
utilise it as a substrate. Labelling with [ ^ P ]  in cell 
culture showed the DNase to be phosphorylated during HSV-1 
infection.
Tryptic peptide analysis of i_n vitro phosphorylated DNase 
by the above kinases when compared to the tryptic peptide
23
analysis of [ ^ P ]  ]_abeiie(i DNase purified from infected 
cells failed to resolve which kinases were responsible 
for the phosphorylation of the DNase in cell culture.
DNase endonuclease activity
The DNase has an endonuclease function as well as 
exonuclease activity. This was studied in an assay 
where only the endonuclease function of the DNase is 
active. A plasmid containing the sequences required 
for the cleavage and packaging of concatenated HSV-1 
DNA was used as a substrate for the enzyme. Under 
the conditions employed in the assays, purified DNase 
had no endonuclease activity. DNase treated with 
protein phosphatases 1 or 2A also had no endonuclease 
activity. High speed supernatants from both infected 
and uninfected cells had endonuclease activities.
When they were used to cleave the substrate described 
above in the presence of purified DNase the pattern of 
digestion was altered from that in the absence of the 
purified enzyme. This suggested that the DNase was 
either affording protection to the plasmid or it was 
being activated by a component(s) of the supernatant.
Samples collected from the various stages of the 
purification of the DNase all exhibited endonuclease 
activity against the plasmid except for the final 
purified enzyme. This may mean that a factor(s) required 
by the DNase for endonuclease activity was lost at the 
DNA Cellulose chromatography step of purification.
The Antiviral xanthates
The antiviral activity of xanthates has been reported 
against a wide range of both DNA and RNA viruses including 
herpes simplex. This activity was reported to have been 
mediated through the inhibition of protein kinases. This 
was investigated using partially purified protein kinases, 
cellular and viral, from HSV-1 infected BHK cells in culture 
and three xanthate compounds D609,D611exo and endo (isomers) 
synthesised by Glaxo Group Research chemists. The xanthates 
inhibited all of the kinases tested at mM concentrations, 
an order of magnitude higher than the concentrations required 
for antiviral activity in cell culture. The best inhibitor
24
was D609 with D611exo and D611endo similar in activity.
Using the HSV-1 encoded US3 kinase the inhibition was 
shown to be competitive with respect to ATP.
Infection of HSV-1 in cell culture in the presence of 
the xanthate D609 with subsequent two dimensional 
electrophoresis and immunoblotting of the purified DNase 
showed that the presence of the xanthate significantly 
reduced the phosphorylation of the DNase. Since the 
xanthates have recently been reported as blocking the 
activation of protein kinase C at the phospholipase C 
level this indicates that the DNase is phosphorylated 
in cell culture by protein kinase C or a kinase activated 
by protein kinase C.
The Ribonucleotide reductase
The viral ribonucleotide reductase is composed of two 
subunits encoded by genes UL39 and UL40 of HSV-1. The 
enzyme has the overall structure c* 2 $ 2 *  w ^t 1^ a small 
subunit (RR2) of 38kD and a large subunit (RR1) of 136kD.
The enzyme catalyses the reduction of ribonucleotides 
to deoxyribonucleotides. The large subunit also contains 
an N terminal protein kinase domain, the function of which 
is as yet unknown.
Modification of ribonucleotide reductase large subunit
Although the intact large subunit was present on immunoblots 
of one dimensional gels, using the two dimensional electro­
phoresis system only a 60kD C terminal fragment of the 
large subunit could be obtained. The fragment was present 
at all time points and allowed comparisons to be made.
The 60kD fragment at 3 - 9 hr. post infection was modified, 
this modification was reduced after 9 hrs. and further 
reduced up to 18 hrs. post infection. Literature reports 
showing that the large subunit is phosphorylated in cell, 
culture allow this result to be interpreted as a :decrease 
in the phosphorylation of the large subunit in the course 
of the infection. No information is available concerning 
the kinase responsible for this, however, the large subunit 
has been shown to undergo autophosphorylation.
CHAPTER 2
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INTRODUCTION
1. Herpes Viruses
1.1 Herpes Viruses (see The Herpes Viruses Vol. 1 - 4
ed Roizman B. 1982 - 1985)
Herpes viruses are a large family of viruses found 
to be widespread in vertebrates including fish, birds and 
mammals. The herpes viruses as a group are characterised 
by: 1. The structure of their virions which consist of an
icosahedral capsid containing the viral DNA, surrounded by 
an amorphous layer known as the tegument, which in turn is 
surrounded by a lipid bilayer containing virally coded 
glycoproteins (Figure 2.1). 2. The basic infectious
procedure, by which viral genes are transcribed by cellular 
RNA polymerase II and viral DNA synthesis and capsid assembly 
take place in the nucleus of the infected cell. The capsids 
then acquire the tegument and the lipid bilayer by budding 
through the inner nuclear membrane (Section 2.1). 3. The
genomes of the herpes viruses are large double stranded DNA 
molecules, 120 - 230 kbp, and highly complex (See Section 1.2).
4. They have the ability to establish a latent infection in
certain cell types in their hosts (Section 1.3).
The herpes viruses are subdivided into three subfamilies 
depending on their biological behaviour. The three sub­
families are the alpha, beta and gamma herpes viruses and 
some examples of each are shown in Table 1.1. The alpha 
herpes viruses tend to replicate quickly in permissive cells, 
killing the host cell. They are also able to establish a 
latent infection in neurons near the site of infection.
The beta herpes viruses relicate slowly in permissive cells, 
causing cell enlargement and eventual cell death. They are 
able latently to infect various tissues. The gamma herpes 
viruses tend to form chronic infections preferentially in 
lymphocytes which they also latently infect. They have also 
been linked to cellular transformation. There are six known 
human herpes viruses, five of these are shown in Table 1.1.
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The sixth virus is human herpes virus-6 (HHV6 ) which can 
proliferate in T or B lymphocytes and has been implicated 
in the transient childhood illness exanthem subitum.
1.2 Herpes virus Genomes (McGeoch 1989)
The genomes of the six human herpes viruses have
been isolated and,their genomes either sequenced completely
(HSV-1, VZV, EBV & HCMV (not published) or partially sequenced
(HHV-6 & HSV-2). The HSV-1 genome of 152 kbp consists of
two unique regions, the unique long (UL) and the unique
small (U ) which are bordered by internal and terminal 
s
repeats (Figure 1.2). The U, and U regions can inverts
with respect to each other and so produce the four possible 
genomic orientations shown in Figure 1.2. The so called 
a sequence is responsible for the genomic inversions (Mocarski 
& Roizman 1982, Chou & Roizman 1985). The a sequence also 
occurs as terminal redundancies and contains the signals 
necessary for the cleavage and packaging of unit genomic 
lengths (Mocarski & Roizman 1982, Stow et al 1983, Varmuza 
& Smiley 1985, Diess et al 1986, Diess 1986).
The HSV-1 genome contains at least 72 genes; 56 in 
U|_, 12 in and one, in each copy of the repeat units, which 
produce 70 distinct proteins, but it is possible that some 
genes remain undiscovered in the genome. When compared to 
HSV-2 the two are very similar, in overall genomic structure, 
they are colinear, and in the sequence homology between their 
respective genes and gene products. The proteins produced 
by the HSV-1 will be discussed in Section 2.2.
The genome of VZV is similar to that of HSV-1 (Figure
1.2) and has a similar gene organization in the Uj_ region.
VZV has 70 genes which encode 67 proteins, most of which 
have counterparts in HSV-1, but some, notably the VZV UL 
genes 1, 2, 13, 32 & 57, have no counterparts in HSV-1.
The VZV genome also lacks equivalents to the HSV-1 Ug 
genes US2, 4, 5, 6 , 11 & 12 and the U L genes UL45 & 56.
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Figure 1.2 The overall structure of the human herpes viruses 
(not drawn to scale)
U-^  = Unique long region MIR = Major internal repeat
Ug = Unique short region = lOOObp regions whose
T R =  Terminal repeat of UT sequences are almost
L L identical
IR^= Internal repeat of U^
TR = Terminal repeat of U
s  ^ s
^ s= Internal repeat of Ug
The arrows below the HSV genome indicate the possible genome 
orientations
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EBV has little overall similarity to the HSV-1 
genome (Fig. 1.2), though genes common to EBV, VZV & HSV-1 
have been found. The genome organization differs in overall 
structure and local gene arrangements. EBV contains no 
equivalents to the genes in the Ug regions of VZV and HSV-1.
29 genes in EBV have been found to have equivalents in VZV 
and HSV-1 by amino acid homology of the predicted gene 
product. 14 genes have tentatively been identified by 
their genomic locus.
The HCMV genome has an overall similarilty to the 
HSV-1 genome but is much larger (Fig. 1.2). The full 
sequence of the HMCV genome has not yet been published but 
from the data available it has been shown that it contains 
a DNA polymerase gene with homology to VZV, EBV & HSV-1.
An equivalent of the HSV-1 glycoprotein B has also been 
located. The Ug region has no similarities with any other 
herpes virus genes and contains around 38 open reading frames 
which make up five multigene families. The HCMV genome 
also contains the a sequence terminal redundancies which 
have been shown to direct cleavage/packaging in defective 
HSV-1 genomes (Spaete & Mocarski 1985).
The genome of HHV-6 has not yet been fully sequenced 
but several homologies to other herpes virus genes have 
been reported. Though the herpes virus genomes vary in 
size, composition and genetic layout, similarities also 
occur. The presence of certain genes in all herpes viruses 
suggests that these were present in the common ancestor of 
the viruses. The other genes acquired by the herpes viruses, 
presumably from their hosts genome , may represent adaptations 
to particular host cells and particular conditions.
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1.3 Latency (Roizman & Sears 1987)
Latency is the ability of a virus to be present 
in cells without undergoing a productive infectious cycle. 
Only limited viral functions occur in this state and the 
process is poorly understood.
In the case of HSV-1, the virus can latently infect 
neurons near the site of the initial productive infection.
The latent virus under certain conditions can be reactivated 
causing a productive infection at or near the site of the 
initial infection e.g. cold sores produced by HSV-1 heal 
with time but occur again at any time.
The viral DNA has been shown to occur in two forms
in the nuclei of latently infected cells. It is either
found integrated into the host cell genome or as circular 
DNA molecules. EBV has also been shown to occur in these
two forms in its latently infected host cells. Viral DNA
has also been shown to be amplified in latently infected 
neurons, but the mechanism involved is not viral in origin 
(i.e. not the viral DNA polymerase) and is not understood.
Animal models have been used to study HSV-1 latency, 
as no cell culture system is available for this, but each 
system has its own drawbacks as outlined in Roizman & Sears 
(1987).
It has been reported that in neurons latently infected 
with HSV-1 certain RNA transcripts exist (Wagner et al 1988, 
Spivack & Fraser 1988) which are known as latency associated 
transcripts or LAT’s. One of the LATTs has been shown to 
be complementary (antisense) to the ICP 0 (cxO) gene (Gordon 
et al 1988, Spivack & Fraser 1988). The function of these 
LAT's remains unclear but they have been shown to decrease 
prior to reactivation of the infectious cycle.
Reactivation of latent virus to a productive infectious 
cycle has been shown to be induced by various conditions 
such as stress. Reactivation of HSV-1 latently infected 
neurons in vitro has been induced by the deprivation of 
nerve growth factor (Wilcox & Johnson Jr. 1987, 1988) and
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by the addition of 5 1Azacytidine to HSV-2 latently 
infected neurons i_n vitro (Stephanopoulos et al 1988). 
The mechanism for the nerve growth factor deprivation 
reactivation is not known but 5 'Azacytidine reduces d 
cytidine methylation in DNA and has been reported to 
activate quiescent virus genes which suggests a role 
for DNA methylation in HSV latency and reactivation.
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2. Herpes Simplex Virus Type 1 Infection
2.1 The Viral Infectious Cycle
The infectious particle, known as the virion, (Fig.
2.1) is composed of the viral DNA enclosed in a protein 
capsid. This nucleocapsid (capsid plus viral DNA) is 
surrounded by an amorphous, protein containing matrix 
known as the tegument which in turn is enclosed by a lipid 
bilayer, which is derived from the inner nuclear membrane 
of infected cells, into which are embedded viral glycoproteins. 
The infectious cycle (Figure 2.2) starts with the binding of 
the virion to a receptor, as yet unknown, on the surface of 
the permissive cell. This binding may initially involve 
cellular heparan sulphate (Lycke et al 1991), it also 
involves the viral glycoproteins on the virion surface and 
can be blocked by various compounds such as heparin and 
polylysine (Langeland et al 1988). The viral glycoproteins 
are also involved in the internalisation of the nucleocapsid 
which involves the fusion of the cell membrane and the virion 
bilayer. Internalisation and subsequent transport of the 
nucleocapsid and associated tegument proteins in someway 
involves the cytoskeleton (Rosenthal et al 1985).
The nucleocapsid is transported to the nucleus where 
the viral DNA is released and circularises (Mocarski &
Roizman 1982).
A component (or components) of the virion, released 
on nucleocapsid entry mediates the shutdown of cellular 
protein synthesis and the degradation of cellular mRNA 
(Fenwick & Clark 1982, Kwong et al 1988).
Viral gene transcription and translation are regulated 
by a sequential cascade mechanism (Honess & Roizman 1974) 
and the viral genes can be divided into three main types: 
immediate-early or oCgenes, early or £>genes and late or genes. 
Transcription utilises the cellular RNA polymerase II enzyme, 
ocgene transcription is initiated by a protein associated 
with the capsid, the <*. transinducing factor (ocTIF), UL48) 
(Kristie & Roizman 1988, Ace et al 1988).
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The cx gene products are involved in the regulation of 
subsequent transcription from the viral genome. The o<. 
genes are also themselves regulated by some of their 
subsequent gene products (Mackerti & Roizman 1982, De Luca 
and Schaffer 1988, Hubenthal-Voss et al 1988). The 
genes are regulated by the products of the CX genes, the 
products of the genes include those involved in viral 
DNA synthesis and replication such as the viral DNA polymerase, 
thymidine kinase and ribonucleotide reductase. The 6 genes 
require DNA synthesis in addition to the trans-acting factors 
for their expression (Mavromara-Nazos & Roizman 1987).
The X genes encode structural proteins involved in the pro­
duction of the protein capsid, the tegument and the glyco­
proteins'.
The viral DNA circularises in the nucleus (Challberg 
& Kelly 1989) and is replicated, probably by a rolling circle 
mechanism, the details of which are not well understood. 
Replication results in the production of large head-to-tail 
viral concatemers. This concatenated viral DNA is cleaved 
to unit genomic lengths, with the cleavage linked to the 
packaging of the genome into the capsid. The signals 
responsible for the cleavage and subsequent packaging of 
viral DNA are contained within the terminally redundant a 
sequence (Vlazny et al 1982, Moscarski & Roizman 1982, Stow 
et al 1983, Varmuza & Smiley 1985, Diess et al 1986, Diess 
1986).
The capsid proteins assemble in the nucleus, along 
with the tegument proteins and the viral glycoproteins 
which are inserted into the inner nuclear membrane (Stephens 
& Compans 1988). The viral DNA is packaged into the 
assembled capsid and its associated proteins and the whole 
structure buds through the inner nuclear membrane into the 
perinuclear space. The perinuclear space is contiguous 
with the endoplasmic reticulum through which the immature 
virion passes. In the C^olgi apparatus the virion glyco­
proteins are processed and the mature virions pass to the 
cell surface via. exocytotic vesicles. These vesicles 
fuse with the cell membrane releasing the virions into the 
extracellular space.
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Figure 2.2 Schematic representation of the HSV-1 
productive life cycle.
The virion binds to a receptor on the cell surface (1) 
and introduces the nucleocapsid into the cell via. a 
membrane fusion event (2). The nucleocapsid is 
transported to the nucleus (3a) and a tegument 
protein mediates the shut-off of host protein 
synthesis (3b). The viral DNA is ejected into 
the nucleus (4) and circularises (5). Thec<mRNA*s 
are transcribed, translocated to the cytoplasm and 
translated (6 ). The ^ proteins mediate transcription 
of the genes (7). T h e ^ m R N A ’s are transcribed* 
translocated to the cytoplasm and translated (8 ). 
f?proteins are involved in DNA metabolism prior to 
viral DNA replication. Cellular chromatin breaks 
down and is marginated to the sides of the nucleus (10). 
Viral replication occurs via rolling circle methods 
(11). $ genes are transcribed, translocated to
the cytoplasm and translated (12). The capsid 
proteins are transported to the nucleus where they 
are assembled (13). Concaten ated viral DNA is 
cleaved and packaged into capsids (14). Nucleocapsids 
bind additional proteins (15). Capsids bud 
through the inner nuclear membrane acquiring a 
lipid bilayer containing viral glycoproteins (16). 
Immature virions are translocated via the peri­
nuclear space to the endoplasmic reticulum (17).
The virion glycoproteins are matured in the Golgi 
apparatus (18) and the mature virions travel via 
exocytotic vesicles (19) to the cell surface where 
the vesicles fuse with the cell membrane releasing 
the virus (20).
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2.2 The HSV-1 Virally Coded Proteins
2.2.1 Viral Proteins
The 70 proteins encoded by the HSV-1 genome (McGeoch 
1989, McGeoch et al 1988) can be loosely divided into the 
three classes into which their genes are grouped, namely 
o(, The (^proteins appear mainly to be involved in
the subsequent regulation of the viral genes, the^proteins 
are mainly enzymes some of which are required for DNA 
metabolism and replication and the # proteins are involved 
in the formation of the virion. The proteins involved 
in control and regulation of the virus life cycle consist 
of the immediate-early proteins and UL48 which is synthesised 
as a ^protein, and is a component of the virion. UL48 or 
the<*-transinducing factor (Ace et al 1988, Kristie & Roizman 
1988),<*TIF, initiates the transcription of theocgenes (IE110, 
UL54, IE175, US1 , US12) by binding to specific sequences in 
the regulatory domains of these genes. Three of these gene 
products IE110, IE175 & UL54 (oroc0,oc4 & e*27 respectively) 
are known to be transcriptional regulatory proteins. The 
(Agene products are known to repress the expression of their 
own genes (De Luca & Schaffer 1988).
The early proteins are predominantly enzymes or have 
functions in viral DNA replication. The enzymes found 
to date are mainly those involved in DNA metabolism (thymidine 
kinase, deoxyuridine triphosphatase, ribonucleotide reductase 
(Section 4)), DNA replication (DNA polymerase, helicase-primase 
ssDNA binding protein, ori binding protein) or DNA repair 
(Uracil DNA glycosylase) . In. vitro studies have shown that 
of the herpes proteins involved in DNA metabolism, 7 are 
necessary and sufficient for origin dependent replication 
(Challberg & Kelly 1989, Wu et al 1988, McGeoch et al 1988, 
Crute & Lehman 1991).
These proteins are the viral DNA polymerase (UL30), 
the helicase-primase (UL5/UL8/UL52), the single stranded 
DNA binding protein (UL29), the origin binding protein (UL9) 
and the processivity enhancing factor (UL42).
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The deoxyribonuclease (UL12) may be involved in 
the cleavage/packaging of concatenated DNA and will be 
discussed further in Section 3.2.
The other group of enzymes so far found in HSV-1 
are the protein kinases, US3 and the predicted kinase of 
UL13. These will be discussed in Section 5.3.2.
The $  proteins include those required for the production 
of the virion, the capsid proteins, the tegument proteins 
and the glycoproteins. The virion consists of ~30 proteins, 
some of which have a purely structural role, e.g. the form­
ation of the capsid (major capsid protein UL19). Other 
proteins, including UL48, the «TIF,or UL41 which is res­
ponsible for the virally mediated host shut-off mechanism 
(Kwong et al 1988), are required in the early stages of 
the virus life cycle for a productive infection to be 
established. Proteins associated with the nucleo capsid 
may also have a role in the packaging of viral DNA into 
newly formed capsids (UL26, UL33, UL6 ).
The seven viral glycoproteins found so far are 
synthesised as # proteins and are inserted into the inner 
nuclear membrane. The glycoproteins are required by the 
virion in order to form an infectious particle. gB is 
required for the entry of the nucleocapsid via a membrane 
fusion event (Stephens & Compans 1988, Cai et al 1988), 
gD is also involved in virus penetration into cells 
(Petrovski et al 1988, Ligas & Johnson 1988), gH is required 
for the virion to be infectious (Desai et al 1988) and gE 
and gl form a complex which acts as an IgG Fc receptor 
(Johnson et al 1988) which may reduce immune cytolysis of 
virally infected cells.
Many of the HSV-1 virally coded proteins have no 
assigned function, but with advancing techniques and increas­
ing sequence information in the various data banks, this is 
not likely to remain the case for long.
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Table 2.3 The HSV-1 Encoded Proteins *
Gene Function (where known) Class
Requirement for 
growth in cell 
culture
IE110
UL1
UL2
UL3
UL4
UL5
UL6
UL7
UL8
UL9
UL10
UL11
UL12
UL13
UL14
UL15
UL16
UL17
UL18
UL19
UL20
UL21
UL22
UL23
UL24
UL25
UL26
UL27
UL28
UL29
UL30
IE transcription regulator
Uracil DNA glycosylase
helicase/primase component 
Virion protein : DNA packaging
helicase/primase component 
ori binding protein
Deoxyribonuclease 
predicted protein kinase
Major capsid protein
glycoprotein H 
thymidine kinase
Virion protein 
DNA packaging 
Glycoprotein B 
Structural protein 
ssDNA bindng protein 
DNA polymerase
oc
£
Gene Function (where known)
Requirement for 
growth in cell
Class culture
UL31
UL32
UL33
UL34
UL35
UL36
UL37
UL38
UL39
UL40
UL41
UL42
UL43
UL44
UL45
UL46
UL47
UL48
UL49
UL50
UL51
UL52
UL53
UL54
UL55
UL56
IE175
US1
US2
US3
US4
US5
US6
Structural protein ^
v
Structural : DNA packaging 0
Virion protein
y
very large tegument protein 
Capsid assembly
Ribonucleotide reductase large subunit f
small " P
host shut off protein 
processivity enhancing factor
Glycoprotein C
Major tegument protein <*TIF
Deoxyuridine triphosphatase
primase/helicase component
IE transcriptional regulator
IE transcriptional regulator 
IE protein
Protein kinase 
Glycoprotein G
Glycoprotein D
x
P
o i
c>4
cx
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Requirement for 
growth in cell
Gene Function (where known) Class culture
US7 Glycoprotein I ^  n
v
US8 Glycoprotein E n
US9 Virion protein n
US10 Virion protein n
US11 n
US12 IE protein n
n = non essential to virus growth in cell culture 
e = essential to virus growth in cell culture
* After McGeo ch et al 1988, McGeo ch 1989 & Baines & Roizman 1991
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2.2.2 Viral Proteins: Cell Culture Requirements
Much of the work that has been reported on productive 
infection by HSV-1 has been done in cell culture systems.
Many groups have noticed that certain viral genes and their 
products are not required for HSV-1 growth in cell culture. 
Mutational . analysis has shown these to include the ribo­
nucleotide reductase, (Goldstein & Weller 1988), thymidine 
kinase (Kit & Dubbs 1963), the US3 protein kinase (Purves 
et al 1987a), glycoprotein C (Heine et al 1974), and all 
but one of the genes in the Us region of the genome, glyco­
protein D being an essential protein. Some of these results 
can be explained by the fact that in the cell culture system 
host DNA metabolising enzymes such as thymidine kinase, 
ribonucleotide reductase and dUTPase are present which can 
compensate for the loss of the viral enzyme. In the animal 
host the cells infected may not be dividing and therefore 
there is a requirement for viral enzymes which can carry out 
the necessary metabolism. Another possible function for 
some of the proteins reported as unnecessary in cell culture 
is in the production of, maintenance of or reactivation from 
the latent form of the virus (Roizman & Sears 1989).
Studies using mutants with deletions in the genes that 
are unnecessary for viral growth in cell culture have shown 
that certain mutants have much lower virulence in animal 
hosts than the wild type virus. This has been found to be 
the case for the ribonucleotide reductase (Cameron et all988), 
the thymidine kinase (Tenser 1991) and the US3 protein kinase 
(Meignier et al 1988). The lower virulence (the ability of 
the virus to infect cells and set up productive infection 
and produce the symptoms of viral infection) of these mutants 
implies that the protein functions are required by the virus 
for a productive infection to be set up in the animal host.
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3. Deoxyribonucleases
3 .1 Deoxyribonucleases In General
Deoxyribonucleases or DNases are the enzymes which
cleave deoxyribonucleic acid in prokaryotes and eukaryotes.
The basic division between DNases is whether they act in 
an endo or exonuclease mode. Endonucleases can cleave DNA 
at internal sites in the molecule (e.g. circular DNA), exo­
nucleases require free termini for their action either 5 ’ or 
3 f termini and therefore intact circular DNA is resistant to 
their action. DNases also differ in the types of DNA they 
cleave, some utilise only double stranded (ds) DNA, others 
single stranded (ss) DNA and some can utilise both, but to 
varying degrees. Some DNases cleave DNA at specific sites 
whilst others cleave it at random. Endonucleases can 
either nick dsDNA (produce a single stranded break) or cleave 
both strands. Exonucleases can work in either a 3 ’— >5* 
or 5^ — *-3’ direction and in a processive (degrades one DNA 
molecule completely before starting a new one) or dispersive 
manner (i.e. degrades one DNA molecule partially before 
dissociating and starting on a new one).
The possible functions of DNases and some examples 
are shown in Table 3.1.
Many of the enzymes shown in Table 3.1 are discrete 
entities which have deoxyribonuclease activity (e.g. Type 
II restriction enzymes) but many are also directly associated 
with other enzyme functions (e.g. E.coli B Type 1 restriction 
enzyme) in a multi subunit enzyme or are domains in a multi 
functional protein (e.g. Exo III, Exo V in E.coli, DNA 
polymerases I, III in E .coli, phage T4 UV DNA incising enzyme), 
some examples of these are given in Table 3.2.
Regulation of DNases varies from source to source and 
depends on the type of enzyme studied. In the case of the 
bacterial restriction enzymes which recognise specific sequences 
in the DNA and cleave at these sites (type II restriction 
enzymes). Regulation is achieved by the fact that if the
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recognition sequence is methylated then the restriction 
enzyme cannot recognise it and cleave at that site. All 
the bacterial sites are methylated and so only foreign DNA 
which is not methylated is recognised and degraded by the 
enzymes.
The DNase's which are involved in the repair of 
damaged DNA are also regulated by their specificity, since 
they will only act on DNA which has been damaged, for example, 
DNA that contains thymidine dimers (For reviews on DNA repair 
see Sancar & Sancar 1988, and Bohr & Wasserman 1988).
The single stranded endonuclease produced by Neurospora 
crassa is first synthesised as an inactive proenzyme (88kDa), 
in new mycelia. As the mycelia age the proenzyme is converted 
to a 61kDa protein which has endonuclease activity towards 
ssDNA and exonuclease activity towards dsDNA and is thought 
to be involved in recombination and DNA repair jin vivo.
During exponential growth the enzyme is cleaved to a 55kDa 
form which is exported to the culture medium and has only 
endonuclease activity towards ssDNA and ss RNA.
In eukaryotes pancreatic DNase I is inhibited by 
globular actin which has been found in pancreatic juice.
It is proposed that actin inhibits the enzyme after secretion 
until it reaches the duodenum where bile from the liver 
neutralises the inhibition of the DNase allowing it to degrade 
DNA.
Much of the work done with DNases has been in genetic 
engineering and molecular biology using the DNases as tools 
rather than studying the enzymes themselves. The type II 
restriction enzymes are widely used in cloning, DNase I or 
SI nuclease is used in "DNA finger printing".
Recent advances in DNase work have included the 
publication of the crystal structure of DNase I and as a 
result of this a possible mechanism of action has been put 
forward (Suck & Oefner 1986). It has also been shown that 
the diptheria toxin A subunit contains an intrinsic endo­
nuclease activity which rapidly degrades host DNA (Chang 
et al 1989).
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3.2 The Deoxyribonuclease of Herpesvirus
A virally induced deoxyribonuclease activity in cells 
infected with HSV-1 was first reported by Keir & Gold in 
1963. The activity was found to be maximal at 8 - 12 hr. 
post infection. The activity was shown by Morrison & Keir 
(1968) to have different properties to the host enzyme and 
was not present in infected cells treated early in infection 
with puromycin or actinomycin D.
The enzyme responsible for this activity has been 
purified from infected cells by various groups (Hoffman & 
Cheng 1978 & 1979, Strobel-Fidler & Francke 1980, Banks 
et al 1983). Discrepancies between the molecular weight 
of the purified enzyme, 49.4kDa by sedimentation^ 90kDa 
by SDS PAGE, have been resolved and the enzyme has a Mr on 
SDS PAGE of around 85kDa. The molecular weight calculated 
from the amino acid sequence of the protein is 67.5kDa.
The DNase has exonuclease activity towards double
stranded and single stranded DNA. It appears to digest
in a dispersive manner in either the 5 * — > 3 ’ or 3 f— > 5 f
direction with the end product being 5 1 monophosphate
deoxyribonucleotides. The exonuclease function has an
24-
absolute requirement for Mg ions (5mM optimum) and other
divalent cations cannot substitute. In the presence of
24- 24- 24- 24-Mg other divalent cations such as Ca , Zn and Mn
become inhibitory. The pH optimum of the exonuclease is
high between 9 - 10 pH units (hence the name alkaline DNase)
and Banks et al (1983) reported no inhibitory pH could be
found. Strobel-Fidler & Francke (1980) showed the high
pH optimum was a feature of the enzyme itself and not the
substrate. The enzyme was found to be inhibited by KC1
concentrations above 0.2M, sulphyryl blocking reagents such
as p-hydroxymercuribenzoate (IC^q 1.9mM) and the polyamines
spermine (IC^^ 0.6mM) and spermidine (IC^q 1.4mM). The
HSV-1 and HSV-2 exonuclease activities failed to activate
calf thymus DNA for the viral DNA polymerase which implied
that both strands were degraded to the same degree (Hoffman
1981) .
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The DNase purified from infected cells also has an endo­
nuclease function (Hoffman & Cheng 1979, Hoffman 1981,
Strobel-Fidler & Francke 1980). The endonuclease activity 
2+ 2 +
requires Mg or Mn ions at 2 mM for optimal activity.
2 +In the presence of Mn ions at concentrations greater than
ImM only endonuclease activity remains. In the presence
2 2 2 of Mg ions, Ca and Zn are inhibitory. The endo­
nuclease function can act on closed circular double stranded 
DNA, preferring super coiled DNA, nicking it to form the 
open circular form. The enzyme then cleaves at the nick
to produce linear duplex DNA. In the presence of the
2 +
exonuclease function (i.e. with Mg ions present) the 
linear DNA is degraded to small oligonucleotides and mono­
nucleotides. The endonuclease appears to preferentially 
recognise ssDNA regions in dsDNA circles. The cleavage
2 "t"appears not to be base specific. In the presence of Mn 
ions the HSV-1 and HSV-2 nucleases cleave opposite nicks 
and gaps in dsDNA. No distinct fragments were produced 
in DNA which contains no nicks. The endonuclease activity 
is also inhibited by the polyamines, and spermine inhibits 
at a 10 fold lower concentration than for the exonuclease 
function.
Using antibodies raised against the enzyme it has 
been shown to be present in the nucleus of infected cells 
(Banks L. et al 1983, Banks L. et al 1985) by 2 hr. post 
infection. At this time it appears diffusely in the 
nucleus but as the infection proceeds it becomes localised 
in globular structures. These workers also reported a 
possible change in antigenic structure of the enzyme 5 - 6  
hr. pi. as shown by the loss of reactivity of the DNase with 
one of their monoclonal antibodies after 5 - 6  hr. pi.
The DNase has been shown to be phosphorylated in 
cell culture (Banks et al 1985). The enzyme has also been 
synthesised, by the micro-injection of mRNA and DNA into, 
Xenopus oocytes (Preston & Cordingley 1982). The protein 
synthesised was around 85kDa and they showed the presence 
of a new exonuclease activity with similar characteristics 
to those reported for the viral DNase. It follows that 
if phosphorylation is required for an active exonuclease 
function, it must be carried out in the oocyte by cellular
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Studies using HSV mutants with temperature sensitive 
lesions provided evidence that the DNase was virally coded 
(Francke et al 1978, Moss et al 1979, Francke & Garret 1982, 
Moss 1986). The DNase has been mapped to the HSV genome 
(Preston & Cordingley 1982) and Costa et al (1983) identified 
a 2.3 kb mRNA which encoded an 82 kDa protein that reacted 
with a monoclonal antibody against the HSV-2 DNase. The 
temperature sensitive mutants showed initially that the 
mutation in the DNase gene was not lethal to the virus. 
Francke & Garret (1982) showed that mutants with a single 
lesion in the DNase gene had a reduced rate of viral DNA 
synthesis at the non-permissive temperature, and the level 
of the viral DNA polymerase activity was also reduced.
Moss (1986) studied this mutant in greater detail and showed 
that the DNase was required for viral DNA synthesis and 
virus growth.
The sequence of the genes of the HSV-1 and HSV-2 
enzymes are known (Draper et al 1986, McGeo ch et al 1986) 
and from this the predicted amino acid sequences have been 
determined. The HSV-1 enzyme has 626 amino acids and 
the HSV-2 620 amino acids. Sequence analysis showed 
significant differences in the amino acid sequences in 
the N terminal domain, compared to the C terminal domain 
which had a high amino acid homology. Computer predictions 
indicated a similar 3D structure. McGeo ch et al (1986) 
showed the HSV-1 enzyme to be related to a sequence in the 
% herpes virus EBV (BGLF5) and a similar enzyme has been 
reported in cells infected with EBV (Clough 1980). It 
was noted that the EBV enzyme lacked 110 amino acids present 
in the N terminal of the HSV-1 enzyme. The possible prod­
uction of a truncated HSV-1 protein was also suggested.
The function of the DNase in herpesvirus infection 
is unknown. The most obvious role is the degradation of 
cellular DNA to provide deoxyribonucleotides for viral 
DNA synthesis. Francke (1977) reported no evidence that 
cellular DNA was degraded during HSV infection and that 
virally ’stimulated1 DNase activity appeared to be directed 
against viral DNA. This was reported from HSV infection 
in cell culture where cells are dividing, but cells infected
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by HSV-1 in an animal host maybe terminally differentiated 
and therefore not dividing. In these conditions the virus 
may be required to degrade cellular DNA for its replication.
When a monoclonal antibody against the DNase was 
used as an affinity column on infected cell extracts, the 
DNase was found to bind large quantities of the major DNA 
binding protein (DBP) (Vaughan et al 1984). Studies using 
virus with a temperature sensitive lesion in the major DBP 
gene showed that the DNase was destabilised, as well as the 
viral DNA polymerase, in infected cells (Littler et al 1983). 
This may implicate the major DNA binding protein in the function 
of the DNase.
The DNase has been shown not to be required for viral 
DNA synthesis in jin vitro replication assays, which requires 
minimally 7 viral proteins: U L9, UL30, UL42, UL29, U L 5 , UL8 
and UL52 and a viral origin of replication (Wu et al 1988, 
McGeoch et al 1988). It may still be required for the 
maturation of concatenated viral DNA into genomic lengths 
with subsequent encapsidation.
Chou & Roizman (1989) showed that they could purify 
the DNase from HSV-1 infected cells by its ability to bind 
to a DNA probe derived from the ’a f sequence of the genome.
The a sequence (see Section 1.2) occurs at the termini of 
the genome (direct repeats) and in the junction between the UL 
& US regions (inverted repeats). The a region has been 
shown not only to be responsible for inversions of the UL 
& USregions of the genome (Mocarski & Roizman 1982, Chou 
& Roizman 1985) but also contains the signals required for 
the cleavage to and packaging of genomic DNA lengths into 
capsids (Vlazny et al 1982, Moscarski & Roizman 1982, Stow 
et al 1983, Varmuza & Smiley 1985, Diess et al 1986, Diess 
1986). The a sequence (Fig. 3.2.1) contains two signals 
Pac 1 and Pac 2 which direct the cleavage of concatenated 
viral DNA at a site in DR1. The cleavage in DR1 does not 
appear to be sequence specific but rather occurs at a certain 
distance from the recognition sites (Fig. 3.2.1).
Pad Pac2
DR1 D^R2^22 (DR4)3 DRl
Ub Uc
Figure 3.2.1a) Structure of the a region of HSV-1
>36bp > 7 bp
a r a
Pac2 Pad
L terminal
DRl
S terminal
Pac2 CGCCGCG 
L terminal
GC rich 32bp TTTTTT GC rich 34bp cleavage site
Pad cleavage site 
S terminal
GC rich 32bp CCCCC GGGGGG TGTGTTTC GGGGGGGG
Figure 3.2.1 b) Cleavage of concatenated DNA by signals in P a d  & Pac2. 
and the structure of the two signals
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The finding that the DNase binds though non- 
specifically, to DNA probes from this region including 
the sites for Pac 1 and Pac 2 may indicate a function 
for the enzyme in the cleavage of viral concatemers into 
unit genomic lengths perhaps as part of a multienzyme 
complex.
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Section 4 Ribonucleotide Reductase
4.1 Cellular Ribonucleotide Reductase
During cell division in the S phase when DNA 
synthesis is underway the cell requires a regulated 
supply of deoxyribonucleoside triphosphates. This 
is achieved, in prokaryotes and eukaryotes, by the 
enzyme ribonucleotide reductase (ribonucleoside 
diphosphate reductase E.C. 1.17.4.1). The enzyme 
reduces ribonucleotides (in most cases the diphosphate 
form although in some cases the triphosphate form can 
be utilised) by means of a protein radical and a metal 
centre. Cysteine residues are involved in hydrogen 
transfer and the final hydrogen donor is cellular 
thioredoxin. The enzyme is under stringent allosteric 
control which involves feedback inhibition by dATP and 
dTTP (Thelander & Reichard 1979, Reichard & Ehrenberg 
1983). The enzymes examined to date fall into three 
classes depending on their subunit composition and 
cofactor requirements (Stubbe 1990). The largest 
group consists of those enzymes which have a subunit 
composition . Their cofactors (on each of the
small subunits) are a binuclear iron centre (Nordlund 
et al 1990), and a protein radical which in this case 
happens to be a tyrosine radical (Larsson & SjBberg 
1986, SjBberg et al 1985). The subunits exist as 
homodimers. The large subunit,^ , (B1 in E.coli, Ml 
in mouse) contains the substrate binding sites^ the sites for 
allosteric control and the cysteine residues involved 
in hydrogen transfer.
The small subunit,^, (B2 in Ecoli, M2 in mouse) 
contains the cofactors described above which are essentf 
ial for catalysis. The catalytic site is formed by the 
binding of the homodimers.
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The second class of reductase has a singled sub­
unit and requires adenosylcobalamin as a cofactor.
It is thought that a protein radical may also be 
involved in the reaction.
The final class of reductase has been the least 
studied, it has a subunit composition cx^ >z and may 
require a binuclear manganese centre and a protein 
radical for catalysis (Stubbe 1990).
The first class of enzyme has been found in both 
eukaryotes and prokaryotes (Caras et al 1985 , Carbon 
et al 1984, Elledge & Davis 1987, Standart et al 1985), 
the other two classes have, so far, only been found in 
prokaryotes (Thelander & Reichard 1979, Stubbe 1990).
4 . 2 Herpesvirus Ribonucleotide Reductases
During infection of tissue culture cells with 
herpesviruses in the presence of hydroxyurea or excess 
thymidine where the cellular ribonucleotide reductase 
was rendered inactive, it was found that viral replic­
ation could still occur (Cohen 1972 a, Cohen et al 1974, 
Cohen et al 1977, Henry et al 1978, Cohen 1972b, Roller 
& Cohen 1976). The enzyme responsible for this activity 
was subsequently shown, in the case of HSV-1, to be a 
virally coded ribonucleotide reductase (Dutia 1983).
The viral enzyme consisted of two subunits, a large 
subunit known as RRt (140K Daltons) and a small subunit 
known as RR2 (40K Daltons) (Preston et al 1984, Cohen E 
et al 1985, Frame et al 1985, Bacchetti et al 1986, Swain 
& Galloway 1986). The subunits form an complex,
as described earlier, and the same cofactors are involved 
(a tyrosine radical and a binuclear iron centre) but the 
enzyme is not under allosteric control (De Leon et al 1977).
Other herpesviruses have been shown to encode ribon­
ucleotide reductases and sequence comparisons of the 
reductase genes in EBV and VZV have shown them to have 
regions of homology, particularly in the C terminal domain 
of RR1 and the whole of RR2, with the HSV-1 and HSV-2 genes 
(Nikas et al 1986, Gibson et al 1984). The HSV-1 and 
HSV-2 RR1 genes have a high degree of homology with the
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other herpes RR1 genes except for the N- terminal 
domains which in both cases appear to have extensions 
when compared to other reductase large subunits (Nikas 
et al 1986). The N- terminal domains of HSV-1 and 2 
large subunits have been found to have sequence homology 
with protein kinases (See Section 5.1.4) and recently 
have been shown to possess intrinsic protein kinase 
activities (Chung T.D. et al 1989, Paradis H. et al 1990). 
The large subunit of HSV-2 has been implicated in the 
transforming potential of the virus (Huszar & Bacchetti 
1983, McLauchlan & Clements 1983, Galloway & McDougall 
1981) and a protein kinase activity could possibly explain 
that role.
Analysis of mutants has shown that the ribonucleotide 
reductase of HSV-1 is not required for virus growth in 
cell culture (Goldstein & Weller 1988a), but temperature 
sensitive mutants in RR1 or RR2 have greatly reduced 
virulence in mice,(10 fold reduction)(Cameron et al 1988).
Further studies using a deletion mutant (deletion in 
RR1 gene) has shown that the ability of the mutant to grow 
in cell culture was dependent on the state of the infected 
cells. The mutant was severely compromised in non dividing 
cells or in cells at 39.5°C (Goldstein & Weller 1988b) 
and it was suggested that the cellular ribonucleotide 
reductase could compensate the deletion in dividing cells. 
Turk et al (1989) showed that, using a similar deletion 
mutant to Goldstein & Weller (1988b), the mutant virus 
could produce cutaneous lesions in guinea pigs and that 
these lesions resulted from the in vivo replication of 
the mutant virus. They concluded that further work was 
required before it could be certain whether the ribonucl­
eotide reductase was essential for the in vivo replication 
of HSV-1.
In vitro the ribonucleotide reductase is inhibited 
by the decapeptide YAGAVVNDL which corresponds to the C 
terminal end of the small subunit (Gaudrea P. et al 1987).
60
The peptide causes the dissociation of the holoenzyme 
into the homodimers CX^ & ^>2 a consequent loss of
activity.
The N terminal domain of the HSV-1 large subunit 
is highly susceptible to proteolysis in infections in 
cell culture which results in the production of a number 
of lower molecular weight species (Lankinen et al 1989). 
Some of the partially degraded subunits are still enzym­
atically active and were located in the nuclei of infected 
cells.
The only known translational modification of the 
HSV-1 enzyme is the phosphorylation of both subunits 
(Preston et al 1984).
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Section 5 Protein Phosphorylation : dephosphorylation
The reversible covalent attachment of phosphate to 
proteins (phosphorylation), and its removal (dephos­
phorylation) , has been found to be a widespread control 
mechanism in both prokaryotes and eukaryotes. Although 
phosphorylation has been the most widely studied, recent 
reports have shown that dephosphorylation may have 
an equally important role in cellular control mechanisms.
Phosphorylation has now been found to be involved 
in virtually all aspects of biochemistry including the 
control of enzymes in central metabolism (Cohen 1985,
Krebs 1985, Hardie et al 1989), protein synthesis (Rhoads
1988), transcription in prokaryotes (Magasanik 1988) and 
eukaryotes (Corden 1990), photosynthesis (Gal et al 1987, 
Wollman & Lemaire 1988, Coughlan 1988), cell division 
(Dumont et al 1989, Featherstone 1989, Gould & Nurse 1989, 
Draetta et al 1988, Moria et al 1989, Dunphy & Newport 
1989, Draetta 1990), intracellular reponses to extra 
cellular stimuli (Cohen 1985), regulation of signal trans­
duction (Katada et al 1985, Zick et al1986, Sagi-Eisenberg 
et al 1989), regulation of T-lymophycte function (Bolen 
& Veillette 1989, Tonks & Charbonneau 1989), release of 
secretory granuoles from adrenal chromaffin cells (Knight 
et al 1988, Burgoyne et al 1988), phermone responses in the 
yeast Saccharomyces cerevisae (Fields 1990) and possible 
regulation of membrane bound guanyl cyclase activity 
(Hanks et al 1988, Chinkers et al 1989) (Table 5.0).
Dephosphorylation of protein phosphates reverses 
the action of protein phosphorylation and so the cell can 
control, via the enzymes responsible for the two activitiesj 
to a high degree the above functions. Dephosphorylation 
of protein phosphates has been implicated as means of signal 
transduction (Tonks & Charbonneau 1989, Alexander 1990) 
and has been shown to be necessary in cell division (Gould 
& Nurse 1989, Moria et al 1989, Dunphy et al 1989).
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5 .1 Protein Kinases
The enzymes responsible for the covalent attachment 
of phosphate to proteins are known collectively as protein 
kinases (Hunter 1987). They catalyse the transfer of the 
$ phosphate group of ATP (and in some cases GTP) to the 
hydroxy amino acids : either serine/threonine or tyrosine.
The kinases are subdivided into protein serine/threonine 
kinases (Edelman et al 1987) and protein tyrosine kinases 
(Hunter & Cooper 1985). Another group of kinases exist 
which transfer the $  phosphate of ATP to lysine or histidine 
residues on the protein substrate (Chen et al 1974, Smith 
et al 1974).
In some cases the transfer of phosphate does not 
require a protein kinase directly and involves the 
transfer of the phosphate group directly between proteins 
(Magasanik 1988, Wilcox et al 1980).
The kinases also differ in their substrate specificity, 
some kinases have only one known protein substrate (e.g. 
rhodopsin kinase Kuhn 1978) and others have a broad range 
of substrates (e.g. protein kinase C Nishizuka Y 1986).
The kinases also have a variety of regulatory effectors.
A short list of protein kinases exemplifying these feat­
ures in shown in Table 5.1.
5.1.1 Regulation of kinase activity
Protein kinases are highly regulated since they 
control much of cellular activity, and this regulation 
can be divided into four types. The first type of 
regulation occurs in those kinases which are domains 
of transmembrane receptors. These domains are protein 
tyrosine kinase activities and are found on the cytosolic 
face of the membrane, (Figure 5.1.1). The binding of 
the ligand to the receptor causes activation of the tyrosine 
kinase activity and the phosphorylation of its substrates (e.g.
epidermal growth factor receptor kinase Cohen S et al 
1982, Cooper J.A. et al 1982). Removal of the ligand 
terminates the kinase activity, the number of receptors 
can also be controlled by endocytosis or at the level of 
transcription or translation.
References:
1. Beebe & Corbin 1986
2. Nishizuka 1986
3. Edelman et al 1987
4. Stull et al 1986
5. Hardie et al 1989
6 . London et al 1986
7. Nurse & Gould 1989
8 . Hathaway & Traugh 1982
9. Kuhn 1978
10. Cohen S. et al 1982
11. Cooper J.A. et al 1982
12. Bolen & Veillette 1989
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Table 5.1 Protein kinases, their substrates and 
regulatory effectors
Protein Serine/threonine kinase
Kinase
cAMP dep
Protein
kinase
Effector
cAMP
Substrate(s) Reference
Phosphorylase kinase 1
Acetyl CoA carboxylase 
myosin light chain 
kinase
cGMP dep
protein
kinase
Protein 
kinase C
Ca2+:
Calmodulin 
dep protein 
kinase 
I
cGMP
Ca2+ DIACYL- 
glycerol
Ca 2 + calmodulin
EGF receptor 
IL-2 receptor 
myelin basic protein
synapsin I 
protein III
II synapsin I
tryptophan hydroxylase 
MAP - 2
III
Myosin,light chain kinase
AMP Protein 
kinase
2 +Ca :Calmodulin Myosin light chain
AMP
phosphorylation 
by a kinase 
kinase
HMG CoA reductase 
acetyl CoA carboxylase 
hormone sensitive 
lipase
Haem
regulated
Protein
kinase
haem elF 2 (X
dsRNA
dependent
protein
kinase
dsRNA elF 2 w
cdc 2 phosphorylation 
by a kinase 
kinase
Casein 
kinase I
Casein 
kinase II
unknown
unknown 
inhibited by 
heparin
amino acyl tRNA 
synthase
glycogen synthase
glycogen synthase 
acetyl CoA 
carboxylase
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Kinase Effector Substrate(s)
S6 kinase unknown ribosoraal
protein S6
Rhodopsin unknown rhodopsin
kinase
Protein tyrosine kinases
EGF receptor EGF p42
kinase
1 P Ic
p56 CD4 or T cell receptor
CD8 receptor ^  subunit
Reference
3
9
10,11
12
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Figure 5.1.1 Regulation of protein kinases
i) receptor-ligand regulated
ii) 2nd messenger regulated
GC Guanyl cyclase
AC Adenylate cyclase
pLC Phospholipase C
pKC Protein kinase C
IPg Inositol trisphosphate
SER Smooth Endoplasmic Reticulum
DAG Diacyclglycerol
MLCK Myosin light chain kinase
Ligand 68
Receptor p> plasma membrane
tyrosine kinase 
domain
SUBSTRATES
(1)
■ligands o
plasma phosphatidyl
inositol
rOH i -— >---
receptors
DAGmembrane
pKC
NK
IP
NV
cGMP cAMP
cGMP 
dep. protein 
, * kinase
cAMP dep. 
protein kinase
2 +2 +SUBSTRATES SUBSTRATES Ca
SER
Calmodulin
2+ other 
Ca : Calmodulin 
dep. kinases 
e.g. MLCK
2 +
Ca :Calmodulin 
dep. Protein kinases
O O
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The second type of regulation involves the 2nd
messengers generated by signal transduction (Figure 5.1.1
(11)) namely cAMP, cGMP, diacyIglycerol (DAG) and inositol
triphosphate (IP,,). The IP,, released from the plasma
2 +membrane brings about the release of Ca from intra­
cellular stores in the smooth endoplasmic reticulum 
(Spat A. et al 1986, Dawson A. 1985), cAMP activates 
the cAMP dependent protein kinase (Beebe & Corbin 1986),
cGMP activates the cGMP dependent protein kinase (Beebe
2 +& Corbin 1986), DAG & Ca activate protein kinase C
2+(Nishizuka 1986) and Ca bound to calmodulin activates
2 "l”a number of kinases including the Ca :calmodulin 
dependent protein kinases I (Edelman et al 1987), II 
(Stull J. et al 1986, Schulman & Lou 1989), III (Edelman 
et al 1987) and the myosin light chain kinase (Stull J. 
et al 1986, Sellers & Aldstein 1986).
The third type of regulation is by intracellularly 
generated activators such as haem which regulates the 
haem regulated protein kinase (London I. et al 1986), 
double stranded RNA which regulates the ds RNA depend­
ent protein kinase (London I. et al 1986), AMP and 
phosphorylation by a ’kinase kinase’ which regulates 
the AMP dependent protein kinase (Hardie D. et al 1989) 
and the regulation of the Schizosaccharomyces pombe cdc2 
protein kinase by phosphorylation (Gould & Nurse 1989).
The last group of kinases have, at this present time, 
no known regulators and they include casein kinases I 
and II (Hathaway & Traugh 1982), and the hormone-stimulated 
ribosomal S6 kinase (Edelman et al 1987).
5.1.2 Site specificity of protein kinases
Many protein kinase substrates have been analysed 
to see which sites are phosphorylated and if there are 
any similarities between sites on different substrates. 
Along with studies using artificial peptides these have 
been used to produce consensus phosphorylation sequences 
for those kinases with broad substrate specificities.
Table 5.2 shows some of these consensus sequences, but 
it must be said that these are not hard and fast sequences 
which can be used to identify possible phosphorylation
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Table 5.2 Protein kinase phosphorylation site motifs*
Protein kinase
cAMP dep protein kinase
cGMP dep protein kinase
protein kinase C
Ca^fCalmodulin dep 
protein kinase II
Casein kinase I 
Casein kinase II
Phosphorylation Site
RRXSX
XSRX
XRXXSXRX
XRXXSX
XS(P)XXSX 
or XEXXSX
XSXXEX
Myosin light chain kinase KRRXXRXXSX
Haem regulated kinase LSELSRR
on elF 2
dsRNA dependent protein SELJSRR
on elF 2 c<
rhodopsin kinase DEASTTVKTETSQVA
EGF receptor kinase TAENAE^YLRVAP
T PF
$ 5 6 ^ ^  RLIEDNEYTAREGAK
For original references see Kemp & Pearson 1990
71
sites on a particular protein as the tertiary structure 
of the protein probably plays some role in determining 
the sites phosphorylated by a particular kinases.
From the table it seems that many of the kinases 
require multiple arginine residues around the site of 
phosphorylation. These are serine/ threonine protein 
kinases. The casein kinases, however, appear to 
require acidic residues as do the protein tyrosine 
kinases.
72
5.1.3 Autophosphorylation of protein kinases
Many of the known protein kinases undergo an 
autophosphorylation event via mainly an intramolecular 
catalytic reaction, but in some cases intermolecular 
catalysis may be involved. Both protein serine/threonine
and protein tyrosine kinases can undergo this phenomenon.
2 +For example, the serine/threonine Ca rcalmodulin dependent 
multifunctional protein kinase II (Schulman & Lou 1989) 
undergoes autophosphorylation at two distinct sites.
This is thought to be involved in the activation and 
deactivation of the enzyme. The EGF receptor tryosine 
kinase also undergoes autophosphorylation at several 
residues on the binding of EGF (Hunter & Cooper 1985).
This event is an intermolecular one brought about by 
receptor oligomerization (Schlessinger J. 1988).
The function of the autophosphorylation may be to 
retain activity in the tyrosine kinase after the removal 
of EGF. The function of autophosphorylation in many 
kinases remains unclear, but it has been suggested that 
autophosphorylation takes place at a pseudo-substrate 
site in the kinase which when phosphorylated is displaced 
and so activates the kinase. It must be noted that in 
some cases autophosphorylation occurs at many sites and 
it is not clear what the significance of this is.
5.1.4 The Primary Sequence of Protein Kinases
The amino acid sequence data for over 30 protein 
kinases is now available and using computer analysis, 
sequence comparisons have shown a region of approximately 
240 amino acids where the homology between protein kinases 
is the greatest. This region corresponds to the catalytic 
domains of the protein kinases and contains residues essent­
ial for catalysis (Figure 5.2). The domain contains resid­
ues conserved in the majority of kinases, both serine/threo­
nine and tyrosine kinases, but the function of many of these 
remains unclear (Kemp & Pearson 1990).
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The sequence motif G-G— G-V represents the nucleotide 
binding sequence, and has been found in many proteins that 
bind nucleotides. Also involved in ATP binding, and shown 
to be essential for kinase activity, is the Lysine residue 
(K) marked with an asterisk in Figure 5.2 (Zoller & Taylor 
1979). The APE motif is thought to be located near or at 
the active side of the kinase.
The presence of these conserved motifs in the catalytic 
domain allows the sequences of putative protein kinases to 
be analysed to see if they contain any of these motifs as 
in the case of the UL13 gene sequence in HSV-1 (Chee et al
1989).
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5.2 Protein Phosphatases
5.2.1 Protein Serine/Threonine Phosphatases (Cohen P. 1989)
In animal cells so far 4 types of protein serine/ 
threonine phosphatase have been identified. The 4 types 
of phosphatase are classified depending on their preference^ 
to dephosphorylate either the or ^  subunits of phosphorylase 
kinase _iri vitro and their requirement for divalent cations 
(Table 5.2.1).
Sequence data for the genes of phosphatases has 
shown that protein phosphatase type 1 (PP1), protein phos­
phatase type 2A (PP2A) and protein phosphatase type 2B 
(PP2B) belong to the same gene family whilst protein 
phosphatase type 2C (PP2C) appears to be distinct.
The 4 protein serine/threonine phosphatases have 
a broad range of overlapping substrates i_n vitro but 
in vivo, this range may be narrowed by their subcellular 
location and specific regulation of the enzymes (Table 5.2.2).
Protein phosphatase type 1 catalytic subunit in 
striated skeletal muscle is found associated with glycogen, 
the sarcoplasmic reticulum and myofibrils. These assoc­
iations are mediated through two subunits, the G subunit 
which binds to glycogen and the M subunit which binds to 
actinomyosin. Thus binding to either of these subunits 
(PP1-G, PP1-M) directs the phosphatase to a specific 
subcellular location with a limited number of substrates.
The catalytic subunit PP-1C is also found bound to the 
inhibitor 2 protein (PP1I) in the cytosol, this can be 
activated by phosphorylation of inhibitor 2 by glycogen 
synthase kinase 3. The physiological significance of
this is unclear. The enzyme in skeletal muscle is
2+regulated by the second messengers cAMP and Ca 
Inhibitor 1 is activated by phosphorylation by cAMP 
dependent protein kinase and the G subunit is also 
phosphorylated by this enzyme which causes release of 
the catalytic subunit into the cytosol and inhibition 
by activated inhibitor 1 .
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Table 5.2.1 Protein Serine/Threonine Phosphatases
PP1 PP2A PP2B PP2C
Subunit of 
Phosphorylase 
kinase 
preferred
<X ex.
Inhibition by 
inhibitor 1 & 
inhibitor 2 Yes No No No
Divalent ion 
requirement Ca
2 + Mg 2+
Inhibition by 
okadaic acid
Subunit 
compos fti on
I ^ Q 2 0 n m
PP1-G
PP1-C )
G subunit; 
PP1-M 
PP1-C )
M subunit;
PP1-I
PP1-C)
12 )
Ij.Q0.2nm -^50^ ^
A B f C 
(PP2A0)
ABC
(PP2A1) 
AC
(PP2A2) 
A B ’ *C
AB Monomeric
C
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O Hydroxymethylglutary1 CoA reductase
A Dopamine & cyclic AMP-regulated phosphoprotein 
- an i^oform of inhibitor 1 found in the brain
* The phosphatases given are not definitive, 
their function has not been proved directly 
but by knowledge of their in_ vivo cellular 
location and studies of their activities 
in vitro
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Table 5.2.2 Protein Serine/Threonine Phosphatases : Substrates
Phosphatase
Substrate
Phosphorylase kinase 
subunit 
subunit
Glycogen Phosphorylase a
Glycogen synthase
Myosin light chain
Ribosomal protein S6
elF2 <*•
HMG CoA reductase 0
6 phospho fructo2-kinase /  
fructose 2, 6 bisphosphatase
Pyruvate kinase 
6 phospho fructol-kinase 
Fructose-1, 6-bisphosphatase 
Acetyl CoA carobxylase 
ATP citrate lyase 
Phenylalanine hydroxylase
Inhibitor 1 
DARPP *
RII of cAMP dep PK 
Calmodulin dep QAMP phosphodiesterase.
in vitro
PP2A, PP2B, PP2C 
PP1
PP1, PP2A 
PP1, PP2A, PP2C 
PP1, PP2A, PP2C 
PP1, PP2A 
PP1, PP2A 
PP1, PP2A, PP2C
PP1, PP2A, PP2C
i PP2B
m  vivo
PP2A
PP-1G
PP1G
PP1G
PP1M
PP-1
PP-1
PP-1
PP2A
PP2B
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Dephosphorylation of inhibitor 1 is by PP2B which is 
2 +regulated by Ca . Hepatic PP1-G is sensitive to
2 +inhibition by phosphorylase a and Ca which prevents
the activation of glycogen synthase. It is also
regulated by insulin.
Protein phosphatase type 2A has been purified 
in four major forms (Table 5.2.1). The catalytic 
subunit C is found associated with subunits A & B 
(PP2A0), subunits A & B f (PP2A1), subunit A (PP2A2) 
or with subunits A & B ’1. The A subunit directly 
interacts with PP2A C and the B, B f, B ,f subunits interact 
with A. The binding of the A & B (or B f, B !f) subunits 
suppresses the activity of the catalytic subunit towards 
certain substrates producing the enzyme in a low activity 
form. In. vitro polyamines (spermine) and basic proteins 
(protamine) stimulate the activity of all forms of the 
enzyme, but the physiological significance of this is not 
understood.
Protein phosphatase type 2B purified from brain
consists of a heterodimer AB. The A subunit contains
the catalytic site and the calmodulin binding site.
2 +The B subunit contains the Ca binding site(s).
The B subunit may also be myristylated in some cases.
2+The enzyme is regulated by Ca levels on which it is 
completely dependent. Calmodulin appears to neutralize 
the effects of an inhibitory 4kD domain on the A subunit.
Protein phosphatase type 2C has been purified as 
a monomeric protein. In rabbit skeletal muscle and liver 
two isozymes have been found. The mechanism of its 
regulation is unknown.
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5.2.2 Protein Tyrosine Phosphatases
The protein tyrosine phosphatases found to date fall 
into two classes, those which are cytosolic and those which 
are domains of integral membrane proteins (Tonks & Charbonneau
1989). Sequence data from the cytosolic protein tyrosine 
phosphatases (PTP) allowed the identification of other 
possible phosphatases. Little is known about the physio­
logical substrates or the regulation of either class of 
PTPase.
The CD45 integral membrane proteins found on cells
of haematopoietic origin contain cytosolic domains which
have homology with PTPases. The protein has intrinsic
phosphatase action i_n vitro but no known physiological
substrates. The CD45 protein has structural homology
with reGeptor prote ins and may repre se nt a new class of
receptor which on binding of their specific ligand initiate
novel signal transduction pathways by protein tyrosine
dephosphorylation. Possible in vivo substrates of the
CD45 phosphatase include fodrin (A & B subunits), the
1 c k.subunit of the CD3 receptor and p56 protein tyrosine 
kinase (Tonks & Charbonneau 1989).
5 .3 Protein Phosphorylation & HSV Infection
(for review Leader & Katan 1988).
5.3.1 Viral Infection & Protein Phosphorylation
In HSV-1 infection of BHK cells in culture certain 
viral and cellular proteins undergo phosphorylation.
The viral proteins which are phosphorylated include the 
immediate early proteins IE 1, 2,3 & 4 (or 0 , 27 , 4 ,
andoC22) (Ackermann et al 1984), the DNase (Banks et al 
1985) , and the large subunit of ribonucleotide reductase 
(Preston et al 1984).
The functional and regulatory significance of these 
phosphorylations is still not understood and it may well 
be that some of the phosphorylations observed are not 
relevant to viral infection.
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Many of the virion proteins of HSV-1 are phosphorylated 
and this appears to be mediated by cellular kinases such as 
casein kinase II (Stevely et al 1985) but again the function­
al significance of these \£> not understood.
5.3.2 HSV Viral Kinases
HSV-1 has been shown to encode a protein kinase 
activity which is the product of the US3 gene (Purves et 
al 1987a, Frame et al 1987) and has equivalent genes in 
HSV-2, VZV (McGeoch & Davison 1986) and PRV (Zhang et al
1990). The protein has been purified to homogeneity 
(Purves et al 1987b) and shows different characteristics 
from cellular kinases (Purves et al 1986a). The enzyme 
is a serine \  threonine kinase, it is not affected by the
physiological effectors of the most common kinases, i.e.
2+cAMP, DAG, Ca , cGMP and it is active at high salt con­
centrations (Katan et al 1985). The enzyme prefers 
basic artifical substrates (protamine) and appears to have 
a different site specifity from known kinases (Purves et 
al 1986b) ^RRXXSZ Z not Glu/Pro^. As yet no physiological 
substrate for the enzyme is known, and no cellular equivalent 
has been found that may give a clue to its function.
The US3 protein kinase is not required for virus 
growth in cell culture conditions (Purves et al 1987a), 
but mutant virus with a deletion in the US3 gene had a 
greatly reduced virulence in mice (Meignier et al 1988) 
which may indicate a role for the kinase in the infection 
of host cells.
Another protein kinase has been postulated in the 
HSV-1 genome by its homology to other protein kinases 
(Smith & Smith 1989, Chee et al 1989). The UL13 gene 
of HSV-1 and its equivalents in VZV, EBV, HCMV and HHV6 
has the characteristic motifs of protein kinases (see 
Section 5.1.4), but as yet the protein products of these 
genes have not been shown to have kinase activity.
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The N terminal extensions of the large subunits of 
ribonucleotide reductase (see Section 4.2) of HSV-2 and 
HSV-1 have been shown to have sequence homology with 
protein kinases and they have both been shown to possess 
intrinsic protein serine/threonine kinase activities 
(Chung et al 1989, Paradis et al 1990). Both of the 
kinase activities undergo autophosphorylation and the 
HSV-1 RR1 has been shown to phosphorylate the small sub­
unit of ribonucleotide reductase.
The HSV-2 RR1 subunit is myristylated (Chung et al
1990) and the enzyme has been found in cytosolic, cyto- 
skeletal and plasma membrane fractions of infected cells. 
The kinase activity of RR1 was found to be stimulated by 
polylysine iji vitro.
The function of these protein kinase domains in 
RR1 of HSV-1 and HSV-2 is not known but the HSV-2 enzyme 
may have a role in the transforming potential of the 
virus. Seuqences containing a large subunit of HSV-2 
are known to cause transformation in hamster cells 
(Hayashi et al 1985, Iwasaka et al 1985).
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Section 6 Antiviral Agents
6 .1 Antiviral Agents in General
In recent years the search for compounds with 
antiviral activity has greatly increased, especially 
in the case of viruses such as human immunodeficiency 
virus-1 (HIV-1) and HSV-1 where vaccines are proving 
difficult to produce (De Clercq 1989, Dimmock, Griffiths 
& Madeley (Ed ) Control of Virus Diseases Part II 1990 
Cambridge University Press). The rationale behind 
many of the known antiviral compounds has been that 
they are nucleoside analogues (Table 6.1) which interfere 
with viral DNA or RNA synthesis in either a specific or 
non-specific manner. More recent attempts to identify 
novel antiviral drugs have concentrated on inhibitors of 
specific viral functions (Cameron 1990). The commercially 
available anti-herpes drug, acyclovir \ 9 ~ (2-hydroxyethoxy- 
methyl) guanine] (Figure 6.1) can only be phosphorylated 
by the virally coded thymidine kinase and so will not 
affect uninfected cells. The mono-phosphorylated form 
of acyclovir is an even more potent inhibitor of viral 
DNA synthesis (Elion et al 1977). The triphosphorylated 
derivative of the compound is produced by cellular enzymes. 
The compound can then be incorporated into viral DNA causing 
termination of the nascent viral DNA chain. The triphos- 
phorylated derivative is also an inhibitor of the viral 
DNA polymerase.
AZT (3* azido-3' deoxythymidine) (Fig. 6.1) the 
commercially available anti-HIV drug does not have the 
same degree of specific inhibition. AZT is phosphorylated 
by cellular enzymes and the triphosphorylated form is a 
highly potent inhibitor of the HIV reverse transcriptase.
The utilisation of this form of AZT by the reverse 
transcriptase leads to premature chain termination of 
nascent viral DNA chains. The fact that AZT can be 
phosphorylated by cellular enzymes leads to the accumulation 
of its intermediary phosphorylated derivatives (e.g. 5 * 
monophosphate form) in dividing non infected cells.
HN
HO
Acyclovir
Dideoxycytidine
NH
Amantadine
0
II
W O  P  C O O H
1
OH
Phosphonoformic acid
.CH
W KI'
v\o— |
Azidothymidine
Ribavirin
CH-CH
Rimanta:dine
Figure 6.1 Structures of known antiviral agents
85
Table 6.1 Antiviral compounds: their target viruses 
and sites of action
Antiviral compound Virus inhibited 
Acyclovir HSV-1, HSV-2
Site of action
Viral DNA 
polymerase
Azidothymidine
(AZT)
HIV-1 Viral reverse 
transcriptase
Dideoxycytidine 
( d d c )
HIV-1 Viral reverse 
transcriptase
Ribavirin Influenza A & B 
respiratory syncytical
virus
viral RNA 
polymerase
Phosphonoformate Cytomegalovirus Viral DNA 
polymerase
Amantadine
Rimantadine
Influenza A Viral
penetration 
and uncoating
Interferon Many viruses, Virus release
including rhinovirus 
& Influenza A & B
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The AZT triphosphorylated form is a poor inhibitor of 
cellular DNA polymerase and so will cause little chain 
termination, but AZT's accumulated derivatives inhibit 
essential enzymes required in DNA metabolism. These 
intermediate derivatives may account for the cytotoxic 
effects of the compound found in many patients (De Clercq
1989) .
6 . 2 Xanthates
Xanthates, a novel group of compounds with the 
general structure shown in Figure 6.2 have been shown 
to have antiviral activity against a wide range of DNA 
and RNA viruses including HSV-1, Vaccinia, Coxsackie B,
SV40 (Sauer G. et al 1984) and HIV-1 (Mellert et al 1988). 
The compounds were shown to have low cytotoxicity at the 
levels used for their antiviral activity. In HSV-1 
infected cells the xanthate D609 (Figure 6.2) inhibited 
viral DNA synthesis but was not incorporated into viral 
or host DNA. Drug resistant mutants to the xanthate 
were not isolated (Sauer G. et al 1984). The compound 
D609 healed HSV-1 and HSV-2 induced skin lesions on 
guinea pigs when applied in an acidic ointment. Viral 
DNA synthesis and virus production were inhibited in 
the skin (Amtmann E. et al 1985a) by the xanthate.
The xanthate D609 was able to interrupt the viral life 
cycle of SV40 in infected cells at any point. Viral 
replication and transcription was inhibited (Sauer G. 
et al 1984) by the compound. In bovine papilloma virus 
transformed cells treatment with D609 resulted in reversion 
of the transformed cells to their normal phenotype with a 
limited iji vitro lifetime and contact inhibition (Sauer G. 
et al 1984, Amtmann E. et al 1985b).
Problems with the acidic pH required for antiviral 
activity (pH 6 .8 ) were solved when it was found that co­
administration of a monocarboxylie acid chain
length had a synergistic antiviral effect at physiological 
pH (pH7.4) (Amtmann E. et al 1987). This effect was found 
to be caused by the fact that the short chain fatty acids
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General structure of the xanthates
^ o — C
D609 (endo/exo)
V //
‘SK
D611 exo
o
D611 endo
Figure 6.2 Structure of the xanthate antiviral agents
(C^q - C ^ )  occupied the same binding site on BSA 
as the xanthate (Music L. et al 1989).
Detailed studies on vesicular stomatis virus 
(VSV) infection indicated that the xanthate D609 
inhibited viral replication and late gene trans­
cription. It was also shown to have significantly 
reduced the phosphorylation of the virally coded NS 
protein which is required for viral transcription 
(Mliller-Decker K. et al 1987). Further studies on 
the signal transduction system of uninfected cells 
suggested that the xanthate acted at the level of 
phospholipase C to block the activation of protein 
kinase C through provision of diacylglycerol (DAG) 
(See Figure 5.1) one of its cellular activators 
(MUller-Decker K. et al 1988).
CHAPTER 3 
MATERIALS & METHODS
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1. Materials
1.1 Chemicals & Reagents
All chemicals used were of Analar grade and obtained 
from appropriate sources as stated below.
1.1.1 Enzymes
3 f5* cyclic AMP dependent protein kinase, snake 
venom phosphodiesterase I, tpck-treated trypsin and 
alkaline phosphatase were obtained from the Sigma 
Chemical Co., Poole, Dorset, U.K..
Acid phosphatase was obtained from BBehringer 
Mannheim (U.K.), East Sussex, U.K..
Protein phosphatases 1 & 2A were a gift from 
Dr.D-G. Hardie, Protein Phosphorylation Group, Dept, of 
Biochemistry, University of Dundee, Dundee, U.K..
The pseudorabies virus protein kinase was a gift 
from Dr. D.P-Leader, Dept, of Biochemistry, University of 
Glasgow, Glasgow, U.K..
1.1.2 Enzyme Assays
Casein, protamine sulphate, histone Ills; histone 
H A S ,  calmodulin, cyclic AMP, ATP, myosin, phosphatidyl 
serine, ethidium bromide, agarose and double stranded calf 
thymus DNA were obtained from the Sigma Chemical Co., 
Poole, Dorset, U.K..
DE81 paper was obtained from Whatman Ltd., Maidstone, 
Kent, U .K ..
1.1.3 Polyacrylamide gel Electrophoresis & Immunoblotting
SDS molecular weight markers, Coomassie brilliant 
blue, 1 - chloro - 4 - napthol, tween 20, protein A 
peroxidase conjugate, BSA (fraction V) and NNN’N 1 tetra 
methylene diamine (TEMED) were obtained from the Sigma 
Chemical Co., Poole, Dorset, U.K..
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Ampholines were obtained from LKB, Sweden.
Nitrocellulose membrane was obtained from Schleicher 
& Schuell, Anderman & Co., Ltd., Surrey, U.K..
PVDF membrane was obtained from Millipore^Watford, 
Hertfordshire, U.K..
The monoclonal antibody Q1 against the HSV DNase 
was a gift from Dr. K. Powell, Molecular Sciences Dept., 
Wellcome Research Laboratories, Beckenham, Kent, U.K..
Anti-mouse IgG (sheep) horse-radish peroxidase 
conjugate was obtained from the Scottish Antibody 
Production Unit, Law Hospital, Carluke, U.K..
The antibodies against the ribonucleotide reductase 
large subunit were a gift from Dr. H. Marsden, and Dr.
H. Lankinen, Institute of Virology, Glasgow, U.K..
I.1.4 Chromatography
DE52 Cellulose, phosphocellulose Pll, and cellulose 
Cll were obtained from Whatman Ltd., Maidstone, Kent,
U.K..
Single stranded DNA cellulose^Sephadex G50^phenyl 
5epharose CL4B, and the Mono Q FPLC column were obtained 
from Pharmacia Ltd., Milton Keynes, U.K..
1.1.5 Tissue Culture
Minimum essential medium, Glasgow modification (GMEM), 
200mM glutamine, 7.5% sodium bicarbonate, trypsin, penicillin: 
streptomycin and new born calf serum were obtained from Gibco- 
BRL, Paisley, U.K..
Essential amino acids, non-essential amino acids and 
vitamins were obtained from Flow Laboratories, Irvine,U.K..
Versene (0.14M NaCl, 2.7mM KC1, 10mMNaHPC>4 , 2.4mM 
KH^PO^, 2mM EDTA, 0.015% phenol red) was prepared and 
autoclaved by the department’s tissue culture staff.
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2 2 2 25cm , 75cm & 150cm sterile tissue culture flasks
were obtained from Corning Glassworks, New York, U.S.A..
1.1.6 Autoradiography
X-ray film was obtained from the Fuji Photo Film 
Co., Ltd., Tokyo , Japan.
1.1.7 Scintillation Fluid
Ecoscint A was obtained from National Diagnostics* 
Aylesbury, U.K..
1.1.8 General
Nonidet P40, undecanoic acid, phenyl methyl sulphonyl 
fluoride (PMSF), ethylene glycol bis ( >^ amino ethyl ether) 
N,N,N’,N’ - tetra acetic acid (EGTA) and tosy1-L-pheny1- 
alanine chloromethyl ketone (TPCK) were obtained from the 
Sigma Chemical Co., Poole, Dorset, U.K..
Poly (dl.dC).Poly (dl.dC) was obtained from Pharmacia 
Ltd., Milton Keynes, U.K..
dATP, dTTP and dGTP were obtained from BBehringer 
Mannheim, East Sussex, U.K..
Bradford reagent was obtained from Biorad Ltd., 
Richmond, California, U.S.A.
Aquacide II was obtained from Calbiochem-Behring 
Corporation, U.S.A..
The restriction enzymes and react buffers were 
obtained from Bethesda Research Laboratories, Cambridge, 
U.K. .
The plasmid G35a was a gift from Dr. N. Stow,
Institute of Virology, Glasgow, U.K..
93
The xanthates were synthesised by chemists at 
Glaxo Group Research, Greenford, Middlesex, U.K., 
by established methods (Moller & Ottel 1967).
The nick translation kit was obtained from 
Amersham International, Amersham, U.K..
1.2 Radiochemicals
Deoxy (5- H) cytidine 5 ’ triphosphate, ammonium
salt, adenosine 5 * ( triphosphate, triethyl
32Pammoni um salt and orthophosphate [ ] in dilute HC1
were obtained from Amersham International pic, Amersham, 
U.K. .
1.3 Cells & Viruses
BHK 2 1 |C13 baby hamster kidney fibroblasts originally 
produced by MacPherson & Stoker (1962) were maintained in 
continuous cell culture.
HSV-1 strain F was obtained from the Institute of 
Virology, Church Street, Glasgow (Ejecito & Kieff 1968).
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Solutions
2.1 Cell Culture Medium
Normal medium: Distilled water 365ml
Minimum essential medium GMEM 
Glasgow modification
50ml
New born calf serum 50ml
7.5% sodium bicarbonatel5ml 
200mM glutamine 10ml
Penicillin/Streptomycin10ml
Phosphate Reduced medium:
Sterile water 244.5ml Phenol Red 0.17mg/ml
Penicillin/Streptomycin 10ml Salts 
New born calf serum 50ml
7.5% sodium bicarbonate 15ml 
200mM gluatime 10ml
essential amino acids 10ml 
non essential amino acids5ml 
vitamins 5ml
2.65mg/ml CaCl9 .6H90 
4 mg/ml KC1 1 1
2mg/ml MgSO ,7H 0 
64mg/ml NaCl
50ml
50ml
50mlD Glucose 45 mg/ml 
Ferric chloride O.lmg/ml 0.5ml
2.2 Viral Infections
Phosphate Buffered Saline PBS
A:
B:
lOg NaCl 
0.25g KC1 
1.44g NaH P0 
0.25g KH2P044
H„0 to J.1
0.25gCaCl2/l
pH to 7.4 with HC1
C: 0.25g MgCl2/l
Solutions A:B:C mixed in the ratio 8:1:1 before use.
Reticulocyte standard buffer RSB
lOmM TrisHCl pH7.5 
lOmM KC1
1.5mM magnesium acetate
Medium K 250mM Tris-HCl pH7.5 
1.25M KC1
50mM magnesium acetate 
50mM 2-mercaptoethanol
PMSF 500mM in DMS0
EGTA 250mM in dilute alkali
2 . 3 Column buffers 
DE Buffer
DC Buffer
Phenyl Sepharose Buffer
2 . 4 DNA work buffers 
STE Buffer
TE Buffer
2 . 5 Assay buffers 
Exonuclease assay buffer
Endonuclease assay buffer 
General kinase assay mix
20mM Tris-HCl pH 7.5 
ImM EDTA 
ImM EGTA 
ImM PMSF
lOmM 2-mercaptoethanol 
10% glycerol
20mM Tris-HCl pH 7.5
50mM KC1
ImM EDTA
ImM EGTA
ImM PMSF
0.5mM dithiothreitol 
20% glycerol 
0.1% NP40
20mM Tris-HCl pH 7.5 
ImM EDTA 
ImM EGTA 
ImM PMSF
lOmM 2-mercaptoethanol
lOmM Tris-HCl pH 8.0 
ImM EDTA 
lOOmM NaCl
lOmM Tris-HCl pH 8.0 
ImM EDTA
500mM Tris-HCl pH 9.0 
20mM MgCl2
lOOmM 2-mercaptoethanol
300mM Tris-HCl pH 7.0 
24mM 2-mercaptoethanol
20mM Tris-HCl pH 7.4 
50mM KC1
lOmM 2-mercaptoethanol
lOmM MgCl
O.lmM ATPo9
0 . 2p Ci S ATP
substrate
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2 .6 Lowry protein estimation 
A
1% potassium sodium tartrate
4% Na2C03 , 0.8% 0.2M NaOH
0.5% CuSO,.5Ho0 4 2
Solutions D & E were prepared just before use 
D: 50:1:1 of A:B:C
E: Folin-Ciocalteau reagent diluted 1:1 with water
2.7 SDS PAGE Solutions
Electrophoresis buffer
Sample buffer
Coomassie stain 
Destain
Silver staining
(Solution A 
stain ^Solution B
28.8g Glycine 
6g Tris 
2g SDS________
H20 to 21
1.25ml 1M Tris-HCl pH 7.0 
5 ml 20% SDS 
2.5ml 2-mercaptoethanol 
2.5ml 1% Bromophenol blue 
10ml glycerol
0.1% Coomassie brilliant blue R250
50% methanol
10% glacial acetic acid
10% methanol
10% glacial acetic acid
0 . 8g AgN03 in 4 ml H 20
21ml 0.36% NaOH, 1.4ml 14.8M NH^OH
Solution A was added dropwise to.B with mixing, and then 
diluted to 100ml with deionised water.
Developer: 0.12ml 1M Citric Acid 
0.25ml 38% formaldehyde 
to 500ml with deionised water
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2.8 2 Dimension gels
Sample buffer Urea 0.57g 
10% NP40 200
ampholines pH 3.5-10 5 0 y 1
2-mercaptoethanol 50 y)1 
1% Bromophenol blue ly 1 
” ~ 300 y  1h 20
Overlay solution
Gel solutions
Urea 1.2g 
ampholines 40 y) 1 
H20 3.9ml
Urea 4.76g
45% Acrylamide, 0.6% bisacrylamide 0.84ml
10% NP40 1 .6ml 
40% ampholines pH3.5-10 0 .4ml 
H20 3.23ml
to polymerize
TEMED 6 yj 1
10% ammonium persulphate 30 ^  1
Interdimensional soaking buffer
0.5M Tris-HCl pH6.8 10ml 
10% SDS 30ml
lOmM dithiothreitol 3ml 
glycerol 10ml
h 20 to 100ml
2 .9 Western Blotting 
Transfer buffer 25mM Tris 
192mM Glycine 
0.02% SDS 
20% methanol
Ponceau S stain 0.1% Ponceau S 
3% TCA 
in H20
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2.9.1 DNase
Blocking buffer 20mM Tris-HCl pH 7.2
0.15M NaCl 
0.5% Tween 20
prepared as a (X10) stock without Tween. The Tween 20 
was added just prior to use.
1st Antibody solution: Blocking buffer containing 5%
heat inactivated horse serum and the Q1 monoclonal at a 
dilution of 1 :1000.
2nd Antibody solution: Blocking buffer without tween
containing 3% BSA and the sheep antimouse Ig G HRP 
conjugate at a dilution of 1 :100.
Developer:
Solution 1 : 20mg l-chloro-4-napthol in 6ml methanol (-20°C)
Solution 2: 30ml of blocking buffer without tween + 20^1
30% H202 .
Solutions 1 & 2 were mixed together just prior to use.
2.9.2 Ribonucleotide Reductase
TBS 20mM Tris-HCl pH 7.5
500mM NaCl
TTBS 20mM Tris-HCl pH 7.5
500mM NaCl 
0.05% Tween 20
Blocking buffer: TBS containing 3% Gelatin
1st Antibody Solution: TTBS containing 1% Gelatin
0 .01% sodium azide and antibody 
20208 at a dilution of 1:50.
Conjugate solution: TTBS containing 1% Gelatin
and the protein A-HRP conjugate at a dilution of 1:1000.
Developer
Solution 1 : 60mg 1-chloro-4~napthol in 20ml methanol
Solution 2: 100ml TBS + 60yl 30%
Solutions 1 & 2 were mixed just prior to use.
2.10 Invitro/In vivo labelled peptides
Transfer buffer 25mM Tris
lOmM Glycine 
0.5mM Dithiothreitol
2.11 Agarose gel Electrophoresis
Sample buffer Glycerol : 0.025% Bromophenol blue
£1:1]
Electrophoresis buffer (xlO)
TBE 108g Tris
55g Boric Acid 
93g edta
\L with H20
Ethidium bromide was included in the final buffer at 
a concentration of 0.5 pg/ml.
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2. Methods
1 Cell Culture
1.1 Subculture of BHK cells
Trypsin: versene (See Materials)
In the ratio 1:4 was warmed to 37°C. The growth 
medium (Materials 2. l) was removed from an 80oz. glass 
winchester (roller bottle) of confluent BHK cells and 
10ml of the trypsin:versene mixture added. This was 
swirled around in the bottle for 3 - 5 mins. and then 
discarded. 15 - 20 ml fresh trypsin: versene was added 
and gently swirled around the bottle and the cells 
observed under an inverted microscope every few minutes. 
When the cells had started to round up the trypsin: versene 
was poured off and the bottle left until the majority of 
the cells had detached from the glass. 20 - 30 ml of 
culture medium was added and the bottle shaken vigorously 
to detach all of the cells. The cell suspension was 
counted using a haemocytometer and new roller bottles 
seeded with 10 x 10^ cells in 130ml culture medium and 
120cm^C02.
1 .2 Propagation of cells from frozen stock
A vial of frozen cells was removed from the liquid
nitrogen vat and immediately placed in a water bath at
37°C. When defrosted the cell suspension was transferred 
2to 25cm tissue culture flasks containing 10ml culture
medium at a seeding level of 0.5 x 10^ cells per flask.
When the cells were confluent, they were subcultured into 
2
150cm flasks until sufficient numbers were obtained to 
seed 80 oz. roller bottles.
101
2 Virus
2 .1 Virus stocks for infection
Confluent roller bottles of BHK cells were taken and 
the culture medium removed. To each was added 50 ml. 
fresh culture medium containing O.Olpfu/cell HSV-l(F).
The roller bottles were left rotating at 37°C for 48 hours 
and then shaken vigorously to remove the infected cells.
The virus suspension was sonicated for 20 mins. in a 
sonicating water bath to release cell associated virus 
particles, and then stored at -80°C.
2.2 HSV-l(F) infection of BHK cells
20 - 30 roller bottles of confluent BHK cells were 
used. After the culture medium had been removed, 20 ml. 
of the virus suspension described in Methods 2.1 was added 
to give infection at 20pfu/cell and the bottles returned 
to 37°C for 1 hour. 60 ml. of culture medium was then 
added to each bottle and they were returned to 37°C and 
left for the required post infection time.
The cells were harvested on ice into PBS (Materials 
2.2) containing ImM EGTA and 1 mM PMSF to inhibit proteolysis. 
The cells were pelleted by centrifugation at 2000 rpm for 
5 mins. in a Beckman TJ6 centrifuge and the pellet resuspended 
in an equal volume of RSB (Materials 2.2) containing ImM EGTA 
and 1 mM PMSF. The cell suspension was left on ice for 
5 mins. then homogenised by 20 strokes in a teflon-glass 
homogeniser. The homogenate was subjected to centrifugation 
at 30,000xg for 30 mins. at 4°C, after the addition of Medium 
K (Materials 2.2) [0.11 x volume of RSB added]. The 
supernatant was either shock frozen in liquid nitrogen and 
stored at -80°C or was used immediately for the purification 
[Methods 6 ] of the enzyme required.
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3 DNA Cellulose Preparation
(after Alberts & Herrick)
m \
3.1 Pretreatment of Cellulose
lOg. of cellulose Cll was washed 3 times in boiling 
ethanol using a distillation flask and heater. The 
cellulose was then washed at the pump with 100ml each of 
0.1M HC1, 1 mM EDTA and lOmM HC1. It was then washed 
with distilled water until the filtrate had a neutral pH 
and lyophilised to dryness.
3.2 Preparation of denatured DNA
3 x 10 ml. aliquots of a solution of 2 mg/ml calf 
thymus DNA, 10 mM K^HPO^ and 1 mM EDTA were heated in 
test tubes at 100°C for 15 mins. The tubes were then 
placed in ice cold water and the solutions made to 
20mM Tris-HCl pH 7.4.
3.3 DNA Cellulose production
The solution prepared in Section 3.2 was placed 
in a clean dry beaker and to it was added the dry cellulose 
(see Section 3.1) with occasional mixing with a glass rod.
The mixture was then spread out in an evaporating dish, 
covered with gauze and left at room temperature until dry 
( 2 - 3  days). The dried mixture was ground to a powder 
with a glass rod and lyophilised overnight. The lyophilised 
powder was suspended in 20 volumes of lOmM Tris HC1 pH 7.4, 
ImM EDTA and left at 4°C for 24 hours. The slurry was then 
washed twice with 10 mM Tris HC1 pH 7.4, 1 mM EDTA and stored 
at -20°C in 10 mM Tris HC1 pH 7.4, ImM EDTA and 0.15 MKC1.
4 Preparation of C. H] labelled DNA
4.1 Synthesis of [3H] DNA
was placed in a 1.5ml ETppendorf 
s. To the tube was added:tube and lyophilised to dryness
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5^1 calf thymus ds DNA (2mg/ml)
Amersham Nick
lOyl Enzyme solution 
(Materials)
2 ^ )V each of dATP, dGTP, dTTP (ImM solutions) 
73 ^  H 20
Solution mixed and incubated at 15°C for 2 hours.
4.2 Purifcation of [?Hl DNA
A 1ml disposable syringe was plugged with a small 
amount of glass wool and sterilised by running 100% ethanol 
through it and allowing it to dry. A 0.9 ml. bed volume of 
Sephadex G50 in STE pH8 (Materials 2.4) was prepared in the 
syringe by centrifugation at 1600 rpm for 4 mins. in a 
Beckman TJ6 centrifuge. The column was washed with
several 100 y\. aliquots of STE pH8 .
The collecting system was then set up as shown in 
Figure 4.2.1 below, the reaction mixture was loaded onto 
the column and it was subjected to centrifugation as above. 
The run through was taken and diluted to 1ml. with STE pH8 .
It was stored in aliquots at -20°C. 10^ >l was added to 5ml.
Ecoscint and placed in a scintillation counter to check 
incorporation.
syringe
G50 column
glasswool
E-ppendorf tube with its 
bottom cut off
Eppendorf tube with a 
hole in its side
[3H] DNA after 
centrifugation Figure 4.2.1 Purification system 
for nick translated [3H] DNA
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5. Enzyme assays
5.1 DNase assay: exonuclease
(after Purifoy et al 1976)
Assay: 20^jl Assaybuffer (Materials 2.5)
10^1 C. H] DNA (Methods 4) 
lOyl sample 
160 pi Water
After mixing, the assays were incubated at 37°C 
for 30 mins. 10^ )1 of a 25mg/ml BSA solution and 1.3ml. 
of a 5% TCA solution were then added and the assays kept 
on ice for 30 mins. They were then subjected to centri­
fugation for 5 mins. in a microcentrifuge. To 1 ml. of 
each supernatant 5 ml. of ecoscint was added and the radio 
activity of the samples measured in a scintillation counter.
5.2 Kinase assays
The general kinase assay mix (Materials 2.5) was 
used for the assay of the US3 protein kinase, protein 
kinase C, casein kinase II and the cAMP dependent protein 
kinase. The substrates used were at a concentration of 
800pg/ml. and were protamine sulphate for US3 protein 
kinase and protein kinase C, casein for casein kinase II 
and histone H A S  for cAMP dependent protein kinase. In 
the cAMP dependent protein kinase assay, cAMP was included 
at a concentration of lOpM. The final volume of all the 
above assays was 0.25ml..
A specific assay for protein kinase C was also used 
and consisted of: 5mM Hepes pH7.5, 12.5mM M g C ^ ,  8mM2 
mercaptoethanol, 0.5mM EGTA, 0.3mM EDTA, 50pM ATP, 0.2 
mg/ml phosphatidyl serine, 0. 2pCi)S [?^PlAT P , 0.17mg/ml BSA, 
1 .2mg/ml histone III-s in a final volume of 0 .12ml.
The assay for calcium: calmodulin dependent protein 
kinase (after Fukunaga K. et al 1982) was 25mMTris-HCl 
pH 7.5, ImM dithio thr eit o l , O.lmMCaC^, lOmM M g C ^ ,  0 . ImM
ATP, 0 . 2^Ci }[L^p]a T P ,100 units calmodulin, 800pg/ml myosin
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in a final volume of 0 .2ml..
The assays were initiated by the addition of the 
enzyme: lOOyl in the case of the 0.25ml and 0.2 ml.
assays and 40^1 in the case of 0.12ml. assays. They 
were incubated either for 30 mins. at 37°C (column assays) 
or 15 mins. at 35°C (xanthate studies).
After incubation lOOyl aliquots of column assays were 
spotted onto 2 cm. x 2 cm. squares of DE81 filter paper 
whilst 3 x 50^1 aliquots of xanthate assays were spotted 
onto a DEAE block filter. In both cases the filters were 
then washed twice for 30 mins. in 20% TCA, then twice for 
15 mins. in 10% TCA. The DE81 filters were then rinsed 
in ethanol, whilst the DEAE block filter was rinsed in 
methylated spirits and both allowed to dry. The Cherenkov 
activity of the DE81 filters was then measured in a scin­
tillation counter whilst the radioactivity of the DEAE 
block filter was measured using a LKB plate scintillation 
counter.
6 . Enzyme Purification
6.1 DNase Purification (after Banks et al 1983)
An extract prepared from 30 roller bottles as 
described in Methods 2.2 was loaded onto a 10 x 1.5cm 
column of DE52 cellulose. The column was then washed 
with 2 column volumes of DE Buffer (Materials 2.3) and 
eluted with a linear gradient of 0-0.5M KC1 in DE Buffer 
(500ml gradient for a 30-40 roller bottle prep.).
Every 2nd fraction was assayed for DNase activity (Methods
5.1) and the active fractions were pooled and dialysed 
against DE Buffer overnight.
The dialysed sample was then loaded onto a 7 x 1.5cm. 
phosphocellulose column and the column washed with 2 
column volumes of DE Buffer. Elution was carried out 
with a linear gradient of 0.1M-0.4M KC1 in DE Buffer 
(Volume 150-400ml.). Every 2nd fraction collected was 
assayed for enzyme activity.
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The active fractions were pooled, and the BSA 
concentration adjusted to 500 ^g/ml.. The preparation 
was dialysed overnight against DC Buffer (Materials 2.3).
The dialysed sample was loaded onto an 8 x 1 cm. DNA 
cellulose column which was composed of a mixture of commercial 
DNA Cellulose (Pharmacia) and denatured DNA Cellulose prepared 
as detailed in Methods 3. The column was washed with 2 
column volumes of DC buffer and eluted using a 0.05M-1M KC1 
gradient (Volume: 100~200ml.). Every 2nd fraction was 
assayed for DNase activity and the active fractions pooled 
and dialysed against DC buffer. The sample was then reverse 
dialysed against Aquacide to reduce the volume, and then 
stored in 1 ml. aliquots at _80°C.
6.2 Kinase Purification
6.2.1 Protein Kinase C (after Kikkawa V. et al 1986)
An extract prepared from 20 - 30 roller bottles as 
described in Methods 2.3 was loaded onto a 10 xl.5cm.
DE52 cellulose column. The column was washed with 2 
column volumes of DE Buffer and then eluted with a 500 ml. 
gradient of 0-0.5M KC1. Every 2nd fraction was assayed 
using protamine sulphate as a substrate (Methods 5.2), 
the active fractions were pooled and dialysed against 
Phenyl Sepharose buffer (Materials 2.3) containing 1M 
(NH^^SO^ overnight.
The dialysed sample was loaded onto an 8 x 0.75 cm. 
Phenyl Sepharose column, which was then washed with 2 
column volumes of Phenyl Sepharose buffer containing 
^ ( N H ^ ^ S O ^ .  Elution was carried out with a 150 ml. 
gradient (1M(NH^)2S0^-0M(NH^)2^0^) followed by 50 ml. 
of Phenyl Sepharose buffer. Every 2nd fraction was 
assayed for protamine kinase activity, the active 
fractions were then pooled and dialysed against DE Buffer.
The sample was then concentrated in Aquacide, made to 
50% glycerol and stored at ~80°C.
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6.2.2 US3 Protein kinase
This purification was essentially the same as that 
for protein kinase C except that this enzyme eluted at 
0.2-0.22MKC1 on DE52 Cellulose. The kinase from 3-4 
DE52 cellulose columns was pooled and concentrated in 
Aquacide before being dialysed against Phenyl Sepharose 
buffer containing lMCNH^^SO^ and subsequent hydrophobic 
interaction chromatography.
6.2.3 Casein kinase II (after McGarvey 1981)
2 rat livers were chopped and homogenised in 10ml.
RSB containing ImM PMSF and ImM EGTA (Materials 2.2).
The homogenate was centrifuged at 30000xg for 30 mins. 
at 4°C and the supernatant loaded onto a 10 x 1.5cm.
DE52 cellulose column. The column was then washed with
3-5 column volumes of DE Buffer and eluted with a 500ml. 
gradient of 0-0.4M KC1. Every 2nd fraction was assayed 
for casein kinase activity. Active fractions were pooled 
and dialysed overnight against DE Buffer containing 0.25 
M KC1.
The dialysed sample was loaded onto a 7 x 1.5cm. 
phosphocellulose column and the column washed with 2 column 
volumes of DE Buffer containing 0.25M KC1. Elution was 
carried out with a 250ml 0.25M-1M KC1 in DE Buffer gradient. 
Every 2nd fraction was assayed for casein kinase activity. 
Active fractions fromO.5-0.75M KC1 were pooled and dialysed 
against DE Buffer. The sample was concentrated in Aquacide, 
made to 50% glycerol and stored at -80°C.
7. Protein Estimation
7.1 Bradford Method
The test solutions were diluted to 800 with distilled 
water and 200^)L Bradford reagent added and mixed immediately. 
Samples were left for at least 5 mins. and then their absorb­
ance at 595nm measured. A standard curve was prepared using 
BSA at specific concentrations and from this the test sample 
protein concentrations were estimated.
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7.2 Lowry Method
The test samples were made to 1.5ml. with distilled 
water and 1.5ml. of solution D (Materials 2.6)added, mixed 
and left for 10 mins. 0.3ml. of solution E (Materials 2.6) 
was added with immediate mixing.
Samples were left for 10 mins. and then their absorb­
ance at 750nm was measured. A standard curve was constructed 
using dilutions of a BSA solution and from this unknown protein 
concentrations were estimated.
8 . Protein Concentration
8 .1 Acetone precipitation
To the sample in a test tube 5 volumes of acetone at 
room temperature was added. The tube was sealed with 
Nescofilm and placed at -20°C overnight. The precipitate 
was collected by repeated centrifugation ina 1 .5ml. £ppen- 
dorf tube in a microcentrifuge (5 mins. per spin). The 
pellet was air dried.
8 .2 TCA precipitation
Samples were made to 1 ml. with distilled water and 
0.1ml. 0.15% sodium deoxycholate added. The sample was 
allowed to stand for 10 mins. at room temperature. 0 .1ml. 
of 72% TCA was then added and after mixing the precipitate 
was collected by centrifugation in a microcentrifuge for 
5 mins. The pellet was washed twice with distilled water.
9. SDS polyacrylamide gel electrophoresis
The gels were prepared using BRL apparatus with a 
thickness of either 1.5mm or 3 mm. The final concentrat­
ion of acrylamide in the main gel was 10%.
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Samples were prepared by the addition of sample 
buffer (Materials 2.7) either to protein precipitates 
(Methods 8 ) or directly to the sample and then heated 
to 100°C for 2 - 5  mins..
MAIN STACKER
£ib mi
30% Acrylamide : 0.8% bisacrylamide 16.6 2 .5
1.5M Tris HC1 pH8.8 12.5 -
0.5M Tris HC1 pH6 .8 - 3.8
h 2o 20.3 8.8
20% SDS 0.25 75*)t
TEMED 1 8 y V 5^1
10% Ammonium persulphate 0.5 0.3
50 15
The gels were set up in a BRL vertical electrophoresis 
system in the electrophoresis buffer (Materials 2.7) and 
run under the following conditions:-
Gel thickness (mm)________ 1st Hr. Next 4-5 hrs. Overnight
1.5 25mA 40mA 10mA
3 40mA 60mA 20mA
10. Protein gel staining
10.1 Coomassie staining
SDS gels were subjected to electrophoresis as 
described in Methods 9. After removal from the electro 
phoresis apparatus each gel was placed in the staining 
solution (Materials 2.7) for 1 - 2  hrs. at room temperature. 
The gel was then removed and placed in the destaining 
solution (Mate'rials 2.7) at 37°C. The gel was destained 
with several changes of solution until the individual 
bands could clearly be seen.
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10.2 Silver staining (after Wray W. et al 1981)
The gel was removed from the electrophoresis
apparatus and placed in a 50% methanol solution using 
double deionised water. The gel was allowed to soak, 
with several changes of 50% methanol, for at least 24
hours. The silver stain was prepared (Materials 2.7)
and the gel soaked in this for 10-15 mins.. The gel 
was then rinsed in double deionised water (2 changes) 
for 1 hr.. The gel was then placed in the developer 
(Materials 2.7) until the first black bands appeared 
then removed and placed in water while the bands continued 
to develop.
11 2 Dimensional gel electrophoresis (after 0'Farrell 1975)
11.1 1st Dimension: Isoelectric focusing gels
The gel tubes were sealed with Nescofilm and 10 cm. x
1.5 mm. gels were poured with a gel solution (Materials
2.8) which had been incubated at 37°C to dissolve the urea.
The gels were overlaid with water and left to polymerize 
overnight. Samples were prepared by the addition of 30^V 
of sample buffer (Materials 2.8) to a protein precipitate, 
(Methods 8), and then it was heated to 100°C for 5 mins..
The samples were loaded onto the 1st Dimension gels then 
overlaid with an overlay solution (Materials 2.8) and run 
under the following conditions:-
Top tank 0.4% Ethanol amine -ve terminal
Bottom tank 0.2% Phosphoric acid +ve terminal
The gels were run at 200V for the first 30 mins.,
300V for a further 3 hrs., 400V overnight and at 500V for 
an hour the next day. The gels were then removed from 
their tubes using a glass syringe and a long needle. They 
were then placed in 5 ml. interdimensional soaking buffer 
(Materials 2.8) for 1 hr. at room temperature.
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11.2 2nd Dimension: SDS gels
A 1.5mm., 10% acrylamide gel was prepared as descibed 
in Methods 9. The 1st Dimension gel was loaded onto the 
stacker gel and sealed using a 1% agarose solution containing 
bromophenol blue. The gel was then subjected to electro 
phoresis under the conditions stated in Methods 9 until the 
dye front had run off the end of the gel. The gel was 
then stained with Coomassie blue (Methods 10.1) or used 
for Western blotting (Methods 12).
12 Western or Immunoblotting
12.1 Transfer conditions
The transfer apparatus was set up in a plastic box 
containing transfer buffer (Materials 2.9)in the following 
order: the plastic holder, rough padding, 2 sheets of
3 mm. filter paper and a nitrocellulose sheet. The 2nd 
Dimension gel or SDS gel was laid on top of the nitro­
cellulose and any air bubbles removed. A further 2 sheets 
of filter paper were then placed on the gel and. then a 
second rough pad followed by the second half of the plastic 
holder. The whole arrangement was then placed in the 
transfer tank and transfer buffer added to cover it.
Transfer was either at 40V for 3 hrs. or 50mA overnight.
plastic holders
nitrocellulose
=».rough pads
filter gel
paper
Figure 12.1.1
System for gel 
transfer to 
nitrocelluloseU
+
direction of r.nrrpnt-
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12.2 Ponceau S staining of nitrocellulose
The nitrocellulose sheet was removed from transfer 
and cut to match the shape of the gel. The sheet was 
then placed in the staining solution (Materials 2.9) for 
30 mins. then rinsed in water. The molecular weight 
markers and proteins were stained red. The markers were 
marked with pencil and the sheet rinsed in water until 
the red staining had disappeared.
12.3 Immuno blotting for the DNase
The destained nitrocellulose sheet was incubated 
in blocking buffer (Materials 2.9) for 1 hr. at room 
temperature then incubated with the 1st Antibody solution 
(Materials 2.9) for at least 2 hrs. at room temperature.
The sheet was then washed with 5 changes of blocking buffer 
for 5 mins. each, rinsed in water for 5 mins. and then 
incubated with the 2nd Antibody solution (Materials 2.9) 
for at least 3 hrs. at room temperature. The sheet was 
then washed with 5 changes of blocking buffer (5 mins. 
each) and rinsed in water. The developer was prepared 
as described in Materials 2.9 and added to the sheet at 
room temperature. The sheet was left until development 
had taken place, then it was rinsed in water, placed 
between filter papers and stored in aluminium foil.
12.4 Immuno blotting for the Ribonucleotide reductase 
(large subunit)
The destained sheet was incubated for 1 hr. in 
2 changes of blocking buffer (Materials 2.9) at 37°C 
and then washed in 2 changes of TTBS (Materials 2.9) for 
5 mins. each. The sheet was then incubated in the 1st 
Antibody solution (Materials 2.9) overnight at room 
temperature, then washed for 15 mins. each in 3 changes 
of TTBS and incubated in the conjugate solution (Materials
2.9) for 1 - 2  hrs. at room temperature. The nitrocellulose 
sheet was washed a further 3 times in TTBS (15 mins.) before 
being rinsed in TBS (Materials 2.9) (2 x 15 mins.).
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The developer was prepared as described in Materials 2.9 
and 20 - 30 ml. added to the sheet, which was left at room 
temperature until development was complete. The sheet 
was then rinsed in water, stored in filter paper and 
wrapped in aluminium foil.
13 Modification of the DNase
13.1 Alkaline phosphatase
Buffer 500mM Glycine pHIO
40mM MgCl2
5mM ZnCl2
Reaction 500^ >\ Buffer
500^ )1 DNase soln (Methods 6.1)
100 units Alkaline phosphatase
The reagents were mixed and incubated at 37°C for 
1 - 2  hrs. The assay was then split into 2 x 500^1 
aliquots. Each 500^)V was made to 1 ml. and TCA precipitated
(Methods 8.2). The pellets were dissolved in 20pL 1st 
Dimension sample buffer and run in the 2 Dimension gel 
system (Methods 11) in a pH gradient 3.5 - 10. One gel 
was coomassie blue stained (Methods 10.l) and the other was 
transferred to nitrocellulose and immuno blotted for the 
DNase (Methods 12.3).
13.2 Acid phosphatase
Buffer 250mM MES pH6.5
5mM EGTA 
5mM MgSO^
Reaction 500yL Buffer
450^)1 DNase (Methods 6.1)
50^1 Acid phosphatase
The reagents were mixed and incubated at 37°C for 
2 hrs. and then treated in the same way as those in 
Methods 13.1.
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13.3 Snake venom phosphodiesterasefafter Yoshihara K.
et al 1978)
2 x 1 ml. aliquots of a DNase solution (Methods 6.1) 
were acetone precipitated (Methods 8 .l) overnight. The 
pellets were washed twice with ethanol : 150mM Tris HC1 
pH7.4 (2:1, v:v), and then dissolved in 200^1 of 0 .1M 
NaOH at 25°C for 30 mins.. The samples were neutralized 
by the addition of 20yV. 1MHC1 and to each sample was added 
20yl lMTris HC1 pH8.0, 4yl 1M MgCl2 and lOpl 10mM 5' AMP.
To one tube was added 20 W9 snake venom phosphodiesterase 
and to the other 20^jL 1^0. The samples were incubated 
at 37°C for 1 hr. then a further 30yg of the enzyme was 
added and the samples incubated for a further 2 hrs., 
after which they were acetone precipitated overnight.
The samples were then run on the 2 Dimension gel system 
(Methods 11) in a pH range 3.5 - 10 and Immuno blotted 
for the DNase (Methods 12).
13.4 Protein phosphatase 1
Phosphatase Buffer 200mM Tris HC1 pH7.0
lOmM Dithiothreitol
Reaction 500^>\ DNase (Methods 6.1)
50^1 buffer
50yV. Protein phosphatase 1
The reagents were mixed and incubated at 30°C for 
1 hr., The sample was then acetone precipitated (Methods
8 .1 ) overnight and run on the 2 Dimension gel system 
(Methods 11) in a pH range 3.5 - 10, then Immuno blotted 
for the DNase (Methods 12).
14 In vitro phosphorylation
These reactions were based on the kinase assays 
given in Methods 5.2. The kinases available were those 
purified in Methods 6.2 (protein kinase C, US3 protein 
kinase, casein kinase II), cAMP dependent protein kinase 
and the PRY protein kinase.
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14.1 1 Dimension in vitro phosphorylation
The assays used were those given in Methods 5.2 
except that the final volume for the US3 protein kinase ?
PRV protein kinase, cAMP dep protein kinase and casein 
kinase II assays was 50^V. . The final volume of the 
protein kinase C assay was 40^ jV» . DNase was used as a 
substrate, as well as the artificial substrates given in 
Methods 5.2, and the& L 32pjATP concentration was 0 . 5 y Ci 
per assay. The assays were incubated at 37°C for 30 
mins., 30yl of SDS sample buffer (Materials 2.7) was 
added and they were heated to 100°C for 5 mins.. The 
samples were then run on 3 mm. 10% acrylamide gels 
(Methods 9), coomassie blue stained (Methods 10.1), dried 
down and subjected to autoradiography at -80°C.
14.2 2 Dimension in vitro phosphorylation
The assays used were those given in Methods 5.2 
except that the final volume of each assay was 1 ml..
The kinases used were cAMP dep protein kinase, protein 
kinase C and US3 protein kinase. 2 assays for each 
kinase were set up, one had an ATP concentration in the 
assay of 2 mM and no L32pU labelled ATP was added to those 
assays. The other set had an ATP concentration in the 
assay of 50yM and 3^jCi ofXL32p[] ATP was added to the assays. 
All the assays were incubated at 37°C for 1 hr., TCA 
precipitated (Methods 8.2) and run on the 2 Dimension gel 
system (Methods 11) pH range 3.5 - 10. The labelled gels 
were then coomassie blue stained (Methods 10.1), dried down 
and subjected to autoradiography at -80°C. The unlabelled 
gels were transferred to nitrocellulose and immuno blotted 
for the DNase (Methods 12).
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3 215 In vivo labelling with L PD orthophosphate
2
In vivo labelling was carried out in plastic 150cm 
tissue culture flasks, 3-5 per labelling experiment.
BHK cells were grown to confluence and 2 hrs. prior to 
infection the culture medium was removed and phosphate 
reduced medium (Materials 2.1) introduced. After 
infection (Methods 2.2) for 1 hr., the virus preparation 
was removed and 20 ml. phosphate reduced medium containing 
l-2MCit32pJ orthophosphate added. After the specified 
infection time the cells were harvested as described in 
Methods 2.2 and the DNase purified as described in Methods
6.1. The purified DNase was then acetone precipitated 
(Methods 8.1), run on the 2 Dimension gel system pH 3.5-10 
(Methods 11), transferred to nitrocellulose and Immuno 
blotted for the DNase (Methods 12). The nitrocellulose 
sheet was then subjected to autoradiography at -80°C.
16 In vitro C32p3 labelled peptides
The kinase assays used were based on those given 
in Methods 5.2, and the kinases used were cAMP dep protein 
kinase, protein kinase C, casein kinase II and the US3 
protein kinase.
In each case 4 x 500 ^)\- assays were set up for each 
kinase using the DNase as a substrate and 25j)Ci tl32p3 ATP 
per assay. Heparin at a concentration of 5yg/ml. was 
included in the US3 protein kinase assays.
The assays were incubated at 37°C for 1 hr., then 
pooled and acetone precipitated (Methods 8.1) overnight. 
The samples were then subjected to electrophoresis on a 
3mm. 10% acrylamide gel (Methods 9). The gel was then 
transferred to PVDF membrane in a similar manner to 
nitrocellulose transfer (Methods 12.1) except that a 
different transfer buffer was used (Materials 2.10), and 
transfer was overnight at 75mA. The membrane was then 
stained with coomassie blue and destained in 50% methanol
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to reveal the molecular weight markers.
The membrane was then dried, wrapped in cling film 
and subjected to autoradiography at room temperature for 
5 - 6  hrs.. The band containing the labelled DNase
was cut out, rehydrated in 500^1 20mMTris HC1 pH7.5 to 
which was added lOO^g tpck-treated trypsin. This was 
allowed to digest overnight at room temperature and the 
membrane removed. The supernatant was chromatographed 
on a Pharmacia Mono Q column using a 0-1MKC1 gradient in 
20mM Tris HC1 pH 7.5 on the Pharmacia FPLC system. The 
lml. fractions were collected and their Cherenkov activity 
measured by a scintillation counter.
17 In vivo labelled peptides
5 plastic roller bottles of BHK cells were grown to 
confluence and 2 hrs. prior to infection phosphate reduced 
medium (Materials 2.1) was placed in the roller bottles.
After infection for 1 hr. the virus was removed and replaced 
by 20-30ml. phosphate reduced medium containing 2mCiC^^PU 
orthophosphate. The infection was left to proceed for 
12 - 15 hrs. and then the cells were harvested as described 
in Methods 2.2 except that NaF was added to 20mM. The 
DNase was purified as described in Methods 6.1 and then 
acetone precipitated (Methods 8.1) overnight. The sample 
was then subjected to electrophoresis on a 3 mm. 10% 
acrylamide gel (Methods 9) and transferred overnight to 
a PVDF membrane at 75mA. The DNase band was cut out and 
incubated overnight at room temperature in 500 ^  20mM 
Tris HC1 pH 7.5 containing lOOpg tpck-treated trypsin.
The supernatant was then chromatographed on the Mono Q 
using a gradient 0-1M KC1 in 20mM Tris HC1 pH7.5 on the 
Pharmacia FPLC system. The 1 ml. samples collected were 
taken and their Cherenkov activity measured by a scintillation 
counter.
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18 DNase endonuclease studies
18.1 Ethanol precipitation
To the DNA sample 0.1 volumes of 3M sodium acetate 
pH6 and 2.5 volumes of cold ethanol (-20°C) were added 
and the mixture was kept on dry ice for 10 mins. The 
DNA was collected by centrifugation for 15 mins. in a 
microcentrifuge, washed with ethanol and lyophilised for 
5 mins.. The pellet was resuspended in TE Buffer (Materials 
2.4) .
18.2 Agarose gel electrophoresis
A 1% agarose solution was made up in TBE (Materials
2.11) and dissolved by heating in a microwave. Ethidium 
bromide was added to a concentration of 0.5^g/ml.. The
agarose solution was allowed to cool to hand heat before
the gel was poured and allowed to solidify.
Samples were prepared by the addition of lOpl of 
sample buffer (Materials 2.11) to the endonuclease assay.
20jJl of this mixture was then run on a gel. The gels 
were run in a horizontal slab electrophoresis system in 
TBS buffer containing 0.5yg/ml Ethidium bromide (Materials
2.11) at 60-100v. for 1 - 2  hours.
18.3 Restriction Enzyme digestions
Enzymes: Hind III, EcoR I & Pst I
Reaction: 3|jl React Buffer x 10 (BRL)
React 3 EcoR I
React 2 (Hind III
(Pst 1 
i v i  Enzyme (= 10 units)
lOul G35a DNA solution (=10ug) or ethanol , 
r \ precipitated
sample
16pl H20
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lacZ
pUC9
Figure 18.1 Plasmid G35a
Nuc. Acid Res. 11 8205 Stow et al (1983)
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The digestions were carried out for 1^ - hrs. at 37°C and 
the samples were then subjected to agarose gel electro­
phoresis (Methods 18.2).
18.4 Endonuclease assays
The standard assay used was 50mM Tris HC1 pH7.0,
4mM 2 mercaptoethanol (Materials 2.5), 5mM M n C ^  and 1 Oyjg 
G35a DNA (Figure 18.1)in a final volume of 30yl.
The reaction was initiated by the addition of the enzyme 
and the incubation, at 37°C, varied depending on the 
experiment. In some experiments poly (dLdC).poly (dLdC) 
was present to prevent non specific protein'.DNA binding 
and in some experiments a series of buffers at different 
p H ’s were used.
19 Xanthate studies
19.1 Kinase partial purification
20 roller bottles of BHK cells were infected and 
harvested as described in Methods 2.2. The cell extract 
was then loaded onto a 6.0 x 2.5 cm. DE52 cellulose column, 
and washed with 2 column volumes of DE Buffer (Materials 2.3). 
Elution was carried out with a 300 ml. gradient 0-0.5M KC1 
in DE Buffer, and 5 ml. fractions were collected. Fractions 
were stored at -20°C.
Protein kinase C and the US3 protein kinase were 
located by protamine kinase assays (Methods 5.2) of the 
column fractions. The protein kinase C fractions were 
then reassayed in a specific protein kinase C assay.
The positions of the other kinases were estimated from 
their known KC1 elution concentrations from DE52 cellulose. 
Specific assays (Methods 2.3) were then carried out to 
determine their positions. In all cases the most active 
fractions were used in the inhibitor studies.
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19.2 Inhibitor studies
The xanthate stock solutions used were ImM, lOmM,
50mM and 1M in water and were stored at -20°C. In the 
assays the xanthates were added after the substrate, the 
labelled ATP was then added and these were incubated at 
35°C for 5 - 10 mins. before the addition of the kinase.
The reactions were then carried out as described in Methods
5.2.
CHAPTER 4 
R E S U L T S
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Section 1 Purification of the DNase
The purification of the DNase was carried out, after 
the method of Banks et al 1983. A broad peak of exo- 
nuclease activity was found on DE52 cellulose chromatography 
of an extract of infected cells. This eluted at 0.1 - 0.25M 
KC1 (Figure 1.1). The exonuclease activity in this peak 
resolved into two peaks on subsequent Phosphocellulose 
chromatography. The DNase eluted at 0.1 - 0.15M KC1 and 
the virally coded DNA polymerase coeluted with the second 
peak at 0.225 - 0.275M KC1 (Figure 1.2).
The DNA polymerase is known to have an. exonuclease 
activity (Weissbach A. et al 1973). The DNase was finally 
purified as a single peak of activity on DNA Cellulose 
chromatography from which it eluted at 0.1 - 0.3M KC1 
(Figure 1.3).
The purity of the final concentrated DNase varied 
from preparation to preparation. In some cases essentially 
a single protein of homogeneous enzyme was found on Coomassie 
blue stained polyacrylamide gels (Figure 1.4). On other 
occasions a small number of additional proteins was seen, 
one of which was normally BSA.
Quantitative and qualitative analysis of a typical 
purification are shown in Table 1.1 and Figure 1.4.
The final purification by a factor of approximately 400 
over the starting material compares favourably with 
pubiished data (Banks et al 1983) . The Coomassie blue 
stained polyacrylamide gel showed that both the DE52 
Cellulose and phosphocellulose DNase pools contained a 
highly complex mixture of proteins (Figure 1.4) which, 
in the particular preparation illustrated were resolved 
into one band which migrated at a molecular weight 85000 
after chromatography on DNA Cellulose.
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This is in agreement with other published data on 
the molecular weight of the enzyme. Coomassie blue 
staining of a two dimensional polyacrylamide gel (Methods 
11) on which a TCA precipitated (Methods 8.2) sample of 
purified DNase had been run (Figure 1.5) also showed a 
single stained region at 85000 Daltons.
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Figure 1.1 DE52 Cellulose chromatography 
(Methods 6.1) of an 18 hr. HSV-l(F) infected 
BHK cell extract (Methods 2.2). Elution was 
carried out using a 250 ml. gradient of 0-500 
mMKCl in DE Buffer (Materials 2.3).
126
D 1
N
A
1  1
A
C
T
I
V
T
Y
x <0
c
p
m
r3
300
200
4
1002
20 30 40 50 60 70
FRACTION NUMBER
DNASE ACTIVITY —I— KCI CONCENTRATION
S3
 
Z
O
 
l>
3
3
H
Z
m
O
Z
O
O
 
—
127
Figure 1.2 Phosphocellulose chromatography 
(Methods 6.1) of fractions 16-31, from the DE52 
cellulose chromatography shown in Fig. 1.1, 
which had been dialysed against DE Buffer 
(Materials 2.3). Elution was carried out using 
a 150 ml. gradient of 0.1-0.4MKC1 in DE Buffer.
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Figure 1.3 DNA Cellulose chromotography 
(Methods 6.1) of fractions 16-22, from the 
Phosphocellulose chromatography shown in Fig.
1.2 which had been dialysed against DQ Buffer 
(Materials 2.3). Elution was carried out using 
a 100 ml. gradient of 0-1MKC1 in DC Buffer.
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Table 1.1 Purification data for a typical DNase 
preparation
Purification
Step
Cell Homogenate
10K spin supernatant
DE52 Cellulose pool
Phosphocellulose pool
Concentrated DNA 
Cellulose pool
Volume Total Protein 
(ml) (mg)
Specific Purification 
Activity *
1A
9.5
83
50
12.5
115 
61 
20.1 
A.5
1.0
19.6x10
25.2x10^
1.7xl06
6.2xl06
75x10
1
1.3
9.0
31.6
382.7
* Specific Activity = cts released from a standard calf thymus DNA
substrate per min. per mg protein at 37°C.
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Figure 1.4 SDS polyacrylamide gel analysis of the 
purification of DNase. Samples collected during the 
purification of DNase from BHK cells infected for 18 hrs. 
with HSV-l(F) (Methods 2.2, 6.1) were subjected to electro­
phoresis (Methods 9) on SDS polyacrylamide gels containing 
10% acrylamide. The gels were stained with Coomassie blue 
(Methods 10.1).
Key Lane 1 Markers Myosin 205kDa, p> Galactosidase 116kDa, 
Phosphorylase b 97.4kDa, BSA 66kDa, Egg Albumin 45kDa, 
Carbonic anhydrase 29kDa.
Lane 2 10K spin supernatant from 18 hr. infected BHK cells
(Methods 2.2).
Lane 3 DNase activity pool from DE52 Cellulose chroma­
tography (Methods 6.1).
Lane 4 DNase activity pool from Phosphocellulose chroma­
tography (Methods 6.1).
Lane 5 Purified DNase from DNA cellulose chromatography 
(Methods 6.1).
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Figure 1.5 Two dimensional polyacrylamide gel electro­
phoresis (Methods 11) of a TCA precipitated (Methods 8.2) 
purified DNase sample. In the first dimension the sample 
was subjected to electrophoresis in a pH gradient of 3.5-10 
(Methods 11.1). In the second dimension an SDS PAGE system 
was used, the gel contained 10% acrylamide (Methods 11.2). 
The gel was stained with Coomassie blue (Methods 10.2).
A marker lane was run at the side of the second dimension.
Key Marker Lane Myosin 205kDa, ^>Galactosidase 116kDa, 
Phosphorylase b 97.4kDa, BSA 66kDa, Egg Albumin 45kDa, 
Carbonic anydrase 29kDa.
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Section 2 Analysis of the DNase by two dimensional 
polyacrylamide gel electrophoresis
2.1 Time course analysis
DNase was prepared from cells harvested at various 
times after infection (Methods 2.2 & 6.1). The purified 
enzyme was subjected to two dimensional PAGE (Methods 11).
The protein was transferred to nitrocellulose and probed 
using an antibody specific for the viral DNase (Methods 12). 
Typical results are shown in Figure 2.1.1. At all times 
apart from 3 hrs. the protein had a highly complex profile 
made up of many spots. These complex profiles indicated 
that the DNase was highly modified, from an early stage 
and throughout the infectious cycle. The enzyme is known 
to be phosphorylated in cell culture (Banks L. et al 1985).
The enzyme from 6 hrs. onwards appeared to be highly 
modified with a large dark spot at lower pi values and in 
some cases smaller spots at higher pi values. At 18 hrs. 
the orientation of the large spot at lower pi values was 
inverted with most of the protein being at the more basic 
end of the spot.
A quantitative analysis of these profiles was carried 
out using Laser densitometry (LKB Ultroscan XL) of the 
photographs of the blots. The data reported in Table
2.2 and confirm the qualitative . evaluation given above.
2.2 The effect of Alkaline phosphatase on the DNase
Alkaline phosphatase treatment (Methods 13.1) of 
DNase purified from 18 hr. infected cells (Methods 2.2 &
6.1) had an effect on its 2D gel profile after immunoblotting. 
The more basic of the smaller spots had increased in area 
(Figure 2.2.1). This indicated a possible reduction in 
the modification of the DNase by the removal of phosphate.
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2.3 The effect of Acid phosphatase on the DNase
Acid phosphatase treatment (Methods 13.2) of DNase 
purified from cells infected for 18 hrs. (Methods 2.2,
6.1) had no significant effect on its 2D gel profile 
after immunoblotting (Figure 2.3.1).
2.4 The effect of Snake venom phospho-diesterase on
the DNase
Snake venon phosphodiesterase treatment (Methods 13.3) 
of DNase purified from cells infected for 12 & 18 hrs.
(Methods 2.2, 6.1) resulted in similar profiles on 2D 
gels after immunoblotting (Figure 2.4.1). These both 
showed a small spot at lower pi values and a much larger 
spot at slightly higher pi values. These profiles were 
both very different from those of the original 12 & 18 
hr. samples. This indicated that a significant reduction 
in their modification had occurred. Snake venon phospho­
diesterase is an exonuclease which degrades poly (ADP-ribose) 
covalently attached to proteins (Yamada M. & Surgimura 1973).
2.5 The effect of Protein phosphatase 1 on the DNase
Protein phosphatase 1 treatment (Methods 13.4) of 
DNase purified from cells infected for 15 hrs. (Methods
2.2, 6.1), resulted in a significant change in its
2D gel profile after immunoblotting (Figure 2.5.1).
The large spot that was present at more acidic pi values 
was altered in size and the orientation within the spot.
This profile also indicated a reduction in the modification 
of the DNase due to the loss of phosphate.
Quantitative analysis of these modified profiles by 
Laser densitometry (LKB Ultroscan XL) of the photographs 
of the blots (Table 2.1) confirmed the qualitative evaluation  ^
given above . Cf*3orC
These results indicate that one form of modification 
of the DNase is phosphorylation. In addition ADP ribose 
or poly (ADP ribose) may be covalently attached to the 
enzyme.
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Figure 2.1.1 Immunoblots of two dimensional poly­
acrylamide gels of DNase purified from cells infected 
for 3, 6, 9, 12, 15 & 18 hrs. (Methods 2.2, 6.1).
In the first dimension the acetone precipitated 
(Methods 8.1) samples were subjected to electro­
phoresis in a 3.5 - 10 pH gradient. The second 
dimension was an SDS polyacrylamide gel containing 
10% acrylamide (Methods 11). The protein on the 
gel was transferred to nitrocellulose by electro­
phoresis (Methods 12.1) and probed with an antibody 
against the DNase (Methods 12.3). A marker lane 
was run at the side of the second dimension and 
was visualised by Ponceau S staining (Methods 12.2) 
of the nitrocellulose membrane before it was blotted.
Marker lane: Myosin 205kDa, p>Galactosidase 116kDa,
Phosphorylase b 97.4 kDa, BSA 66kDa, Egg Albumin 
45kDa, Carbonic anhydrase 29kDa.
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Figure 2.2.1 Imraunoblot of a two dimensional polyacrylamide 
gel of DNase purified from cells infected for 18 hrs. (Methods
2.2, 6.1) and treated with alkaline phosphatase for 2 hrs. 
(Methods 13.1). In the first dimension the TCA precipitated 
sample (Methods 8.2) was subjected to electrophoresis in a 
pH gradient of 3.5 - 10. The second dimension was an SDS 
polyacrylamide gel containing 10% acrylamide (Methods 11).
The protein on the gel was transferred to nitrocellulose by 
electrophoresis (Methods 12.1) and probed with an antibody 
against the DNase (Methods 12.3). A marker lane was run 
at the side of the second dimension and was visualised by 
Ponceau S staining of the membrane (Methods 12.2). Marker 
lane Myosin 205kDa, ^Galactosidase 116kDa, Phosphorylase b 
97.4kDa, BSA^kDa, Egg albumin 45kDa, Carbonic anhydrase 
29kDa.
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Figure 2.3.1 Immunoblot of a two dimensional polyacrylamide 
gel of DNase purified from 18 hr. infected cells (Methods 2.2,
6.1) and treated with Acid phosphatase for 2 hrs. (Methods
13.2). The TCA precipitated sample (Methods 8.2) was 
subjected to electrophoresis in the first dimension in a 
pH gradient of 3.5-10. The second dimension was an SDS 
polyacrylamide gel containing 10% acrylamide (Methods 11).
The protein on the gel was transferred to nitrocellulose by 
electrophoresis (Methods 12.1) and probed with an antibody 
against the DNase (Methods 12.3). A marker lane was run 
at the side of the second dimension and was visualised by 
Ponceau S staining (Methods 12.2). Marker lane Myosin 
205kDa, ^?Galactosidase 116kDa, Phosphorylase b 97.4kDa,
BSA 66kDa, Egg Albumin 45kDa, Carbonic anhydrase 29kDa.
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Figure 2.4.1 Immunoblots of two dimensional polyacrylamide 
gels of DNase purified from cells infected for either 12 or 
18 hrs. (Methods 2.2., 6.1) and treated with snake venom 
phosphodiesterase for 3 hrs. (Methods 13.3). The acetone 
precipitated samples (Methods 8.1) were subjected to electro­
phoresis, in the first dimension in a pH gradient of 3.5-10 
and in the second dimension on an SDS polyacrylamide gel 
containing 10% acrylamide (Methods 11). The protein in 
the gels was then transferred to nitrocellulose by electro­
phoresis (Methods 12.1) and probed with an antibody against 
the DNase (Methods 12.3). A marker lane was run at the side 
of the second dimension and was visualised by Ponceau S 
staining (Methods 12.2). Marker lane Myosin 205kDa,
^>Galactosidase 116kDa, Phosphorylase b 97.4kDa, BSA 66kDa, 
Egg Albumin 45kDa, Carbonic anhydrase 29kDa.
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Figure 2.5.1 Immunoblot of a two dimensional polyacrylamide 
gel of DNase purified from cells infected for 15 hrs. (Methods
2.2, 6.1) and treated with Protein phosphatase 1 for 1 hr. 
(Methods 13.4). The acetone precipitated sample (Methods 8.1) 
was subjected to electrophoresis, in the first dimension in 
a pH gradient of 3.5 - 10 and in the second dimension on an 
SDS polyacrylamide gel containing 10% acrylamide (Methods 11). 
The protein on the gel was transferred to nitrocellulose 
(Methods 12.1) and probed with an antibody against the DNase 
(Methods 12.3). A marker lane was run at the side of the 
second dimension and visualised by Ponceau S staining (Methods
12.2). Marker lane Myosin 205kDa, Galactosidase 116kDa, 
Phosphorylase b 97.4kDa, BSA 66kDa, Egg Albumin 45kDa,
Carbonic anhydrase 29kDa.
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Table 2.1 Quantitative analysis of the DNase time
course profiles and modified DNase profiles 
by laser densitometry
% area of each region in the large 
spot at more acidic pi values
3.5+.^ - 10
Profile
6 h r . 10% 75% 15%
9 h r . 35% 43% 22%
12 hr. 16% 75% 9%
15 h r . 
18 h r .
33%
10%
38%
33%
29%
57%
Acid phosphatase 
treated 18 hr. DNase 20% 48% 32%
SVP treated 12 hr 
DNase 1 1% 89%
SVP treated 18 hr 
DNase 4% 96%
PP1 treated 15 hr. 
DNase 12% 17% 71%
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Figure 2.6
Quantitative analysis of the DNase 
time course profiles and modified 
DNase profiles by laser densitometry
AC: Acid phosphatase treated 18 hr.
DNase
SVP12: Snake Venom Phosphodiesterase 
treated 12 hr. DNase
SVP18: Snake Venom Phosphodiesterase 
treated 18 hr. DNase
PP1: Protein Phosphatase 1 treated 15 hr.
DNase
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3 Phosphorylation : in vitro & in vivo
3.1 Phosphorylation : in vitro
The purified DNase was incubated iji vitro with protein 
kinases in the presence ofjff^] ATP. The sample was 
then subjected to electrophoresis on one dimensional poly­
acrylamide gels. The autoradiographs of these gels
(Figures 3.1.1, 3.1.2, & 3.1.3) showed that of the kinases
used only one could not phosphorylate the protein. Casein 
kinase II, cAMP dependent protein kinase (Figure 3.1.1) 
and protein kinase C (Figure 3.1.3) were all able to phos- 
phorylate the DNase under the conditions employed. The 
PRV virus kinase (Figure 3.1.2) was unable to utilise the 
DNase as a substrate and the HSV-1 US3 protein kinase 
(Figure 3.1.3) may have been able to phosphorylate the 
DNase but because of the impure nature of this preparation 
of the kinase the result was not conclusive. However,the 
autoradiographs from the two dimensional gel analysis of 
the jln vitro phosphorylations (Figures 3.1.4, 3.1.5, 3.1.6) 
showed that the HSV-1 US3 protein kinase was able to 
phosphorylate the DNase (Figure 3.1.6).
The autoradiographs also showed that the incorporated 
was present almost exclusively in the large spot at 
lower pi values (see Results Section 2). This may confirm 
that the spot at lower pi values contains the phosphorylated 
enzyme.
The Immuno blots of the two dimensional gels of the 
in vitro phosphorylations (Figure 3.1.7) showed a similar 
pattern to the autoradiographs, but in the case of protein 
kinase C and cAMP dependent protein kinase (Figure 3.1.7) 
the spots at higher pi values were present. Since they 
were not present in the autoradiographs it again confirms 
that the spot at lower pi values contains the phosphorylated 
DNase.
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3.2 Phosphorylation : in vivo with L inorganic phosphate
DNase was purified from infected cells labelled with 
£32p~j inorgan-LC phosphate for 1 - 6  hr. post infection and 
subjected to two dimensional gel analysis and immunoblotting. 
The autoradiograph (Figure 3.2. la) showed the label to be 
distributed in the large spot at lower pi values. This 
confirmed that this was the region which contained the 
modified DNase.
During the purification of the labelled enzyme 
unlabelled DNase was added to stabilize it and so the 
immunoblot (Figure 3.2.1b) provided evidence that it 
was the DNase alone that was responsible for the pattern 
seen on the autoradiograph.
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Figure 3.1.1 Ijl vitro phosphorylation of the DNase by 
casein kinase II and cAMP dependent protein kinase. DNase 
purified from cells infected for 18 hrs. (Methods 2.2, 6.1) 
was incubated with casein kinase II (Methods 6.2.3) or cAMP 
dependent protein kinase (Materials) in the presence of $  
[32pjAip (Methods 14.1). The samples were then subjected 
to electrophoresis on an SDS polyacrylamide gel, 3 mm. thick 
containing 10% acrylamide (Methods 9). The gel was stained 
with Coomassie blue (Methods 10.1), dried and subjected to 
autoradiography at -80°C.
Key: Marker lane Myosin 205kDa, (3Galactosidase 116kDa, Phos-
phorylase b 97.4kDa, BSA 66kDa, Egg albumin 45kDa, Carbonic 
anhydrase 29kDa.
Lane 1 = CKII + [32p]ATP
Lane 2 = CKII + DNase + X [ 32p]ATP
Lane 3 = CKII + DNase + heparin + & [ 32p]ATP
Lane 4 = CKII + DNase + cAMPdep.PKinhibitor + $ [32p]ATP
Lane 5 = CKII + Casein [32p]ATP
Lane 6 = cAMPdep.PK +tf[32p]ATP
Lane 7 = cAMPdep.PK + DNase +tf[32p]ATP
Lane 8 = cAMPdep.PK + DNase + heparin + ^ [ 32p]ATP
Lane 9 = cAMPdep.PK + DNase + cAMPdep.PKinhibitor + $ [ 32p]ATP
LanelO = cAMPdep.PK + histone H A S  + V [ 32p]ATP
IM:
12 3C5
Figure 3.1.2 JEn vitro phosphorylation of the DNase by the 
PRV viral kinase. D Nase purified from cells infected for 
18 hrs. (Methods 2.2., 6.1) was incubated with PRV viral 
kinase (Materials) in the presence o fjf [32p] ATP (Methods
14.1). The samples were then subjected to electrophoresis 
on an SDS polyacrylamide gel, 3 mm thick containing 10% 
acrylamide (Methods 9). This was stained with Coomassie 
blue (Methods 10.1), dried and subjected to autoradiography 
at -80°C.
Key Lane 1 = Kinase + ^  P 2pl ATP
Lane 2 = Kinase + DNase + 1! P2p] ATP
Lane 3 = Kinase + heparin + DNase + t  c32pi ATP
Lane 4 = Kinase + cAMPdepPKinhibitor + DNase + ^ ATP
Lane 5 - Kinase + histone H A S  + # P 2p] ATP
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Figure 3.1.3 Iji vitro phosphorylation of the DNase by 
protein kinase C and the US3 protein kinase. DNase purified 
from cells infected for 18 hrs. (Methods 2.2, 6.1) was 
incubated with protein kinaseC(Methods 6.2.1) or the US3
. Q O
protein kinase (Methods 6.2.2) in the presence of $[ ^  ATP
(Methods 14.1). The samples were then subjected to electro­
phoresis on an SDS polyacrylamide gel, 3 mm thick containing 
10% acrylamide (Methods 9). The gel was stained with ^oomassie 
blue (Methods 10.1), dried and subjected to autoradiography at 
-80°C.
Key: Marker lane Myosin 205kDa, Galactosidase 116kDa, Phos- 
phorylase b 97.4kDa, BSA 66kDa, Egg albumin 45kDa, Carbonic 
anhydrase 29kDa.
Lane 1 = pKC + histone Ills + i r323 ATP
Lane 2 = pKC + X I32*} ATP
Lane 3 = pKC + histone Ills + 5" t32g ATP - Ca2+
Lane 4 = pKC + histone Ills + $ L32^ ATP - phosphatidylserine
Lane 5, = pKC + DNase + ft [32$ ATP
Lane 6 = pKC + histone Ills + ^ C32^ ATP
Lane 7 = US3pK + histone H A S  + X [32 j^ ^TP
Lane 8 = US3pK + histone IIAS + heparin + If ATP
Lane 9 = US3pK + DNase + s  P 2I ATP
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Figure 3.1.4 I_n vitro phosphorylation of DNase by protein 
kinase C. DNase purified from cells infected for 18 hrs. 
(Methods 2.2, 6.1) was incubated with protein kinase C 
(Methods 6.2.1) in the presence of H [32p]ATP (Methods 14.2). 
The sample was then TCA precipitated (Methods 8.2) and 
subjected to two dimensional polyacrylamide gel electro­
phoresis (Methods 11). In the first dimension a pH range 
of 3.5 - 10 was employed and in the second dimension the 
SDS polyacrylamide gel contained 10% acrylamide. The gel 
was stained with Coomassie blue (Methods 10.1), dried and 
subjected to autoradiography at -80°C.
Marker lane Myosin 205kDa, jbGalactosidase 116kDa, Phos- 
phorylase b 97.4kDa, BSA 66kDa, Egg albumin 45kDa, Carbonic 
anhydrase 29kDa.
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Figure 3.1.5 Ln vitro phosphorylation of the DNase by cAMP 
dependent protein kinase. DNase purified from cells infected 
for 18 hrs. (Methods 2.2, 6.1) was incubated with cAMP dep 
protein kinase (Materials) in the presence of i i32p] ATP (Methods
14.2). The sample was then TCA precipitated (Methods 8.2) 
and subjected to two dimensional polyacrylamide gel electro­
phoresis (Methods 11). In the first dimension a pH gradient 
of 3.5 - 10 was employed and in the second dimension the 
SDS polyacrylamide gel contained 10% acrylamide. The gel 
was stained with Coomassie blue (Methods 10.1), dried and 
subjected to autoradiography at -80°C.
Marker lane Myosin 205kDa, Galac t osidase 116kDa, Phos- 
phorylase b 97.4kDa, BSA 66kDa, Egg albumin 45kDa, Carbonic 
anhydrase 29kDa 
 > position of the DNase.
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Figure 3.1.6 Ln vitro phosphorylation of the DNase by the 
HSV-1, US3 protein kinase. DNase purified from cells 
infected for 18 hrs. (Methods 2.2, 6.1) was incubated with 
the US3 protein kinase (Methods 6.2.2) in the presence of 
i [32p]ATP (Methods 14.2). The sample was then TCA precipitated 
(Methods 8.2) and subjected to two dimensional polyacrylamide 
gel electrophoresis (Methods 11). In the first dimension 
a pH gradient of 3.5 - 10 was employed and in the second 
dimension the SDS polyacrylamide gel contained 10% acrylamide. 
The gel was stained in Coomassie blue (Methods 10.1), dried 
and subjected to autoradiography at -80 C.
Marker lane: Myosin 205kDa, [3Galactosidase 116kDa, Phos-
phorylase b 97.4kDa, BSA 66kDa, Egg albumin 45 kDa. Carbonic 
anhydrase 29kDa.
 > position of the DNase.
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Figure 3.1.7 I_n vitro phosphorylation of the DNase 
by protein kinase C, cAMP dep. protein kinase and 
the US3 protein kinase. DNase purified from cells 
infected for 18 hrs. (Methods 2.2.,6.1) was incubated 
with protein kinase C (Methods 6.2.1), cAMP dep. 
protein kinase (Materials) or the US3 protein kinase 
(Methods 6.2.2) in the presence of 2mM ATP (Methods
14.2). The samples were then TCA precipitated 
(Methods 8.2) and subjected to two dimensional gel 
electrophoresis (Methods 11). In the first dimen­
sion a pH gradient of 3.5 - 10 was employed and in 
the second dimension the SDS polyacrylamide gel 
contained 10% acrylamide. The protein was then 
transferred to nitrocellulose by electrophoresis 
(Methods 12.1) and probed with an antibody against 
the DNase (Methods 12.3). A marker lane was run 
at the side of the 2nd dimension and was visualized 
by Ponceau S staining (Methods 12.2).
Marker lane: Myosin 205kd, Galactosidase 116kd,
Phosphorylase b 97.4kd, BSA 66kd, Egg Albumin 45kd, 
Carbonic anhydrase 29kd.
a = DNase phosphorylated by protein kinase C
b = DNase phosphorylated by cAMP dep. protein kinase
c = DNase phosphorylated by US3 protein kinase
o = DNase
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Figure 3.2.1 In. vivo labelling of the DNase with 
inorganie phosphate. DNase was purified from 
cells infected for 6 hrs. (Methods 2.2, 6.1) and 
which had been labelled with [p^] Pi for 1 - 6  hrs. 
post infection (Methods 15). The purified DNase 
was acetone precipitated (Methods 8.1) and subjected 
to two dimensional polyacrylamide gel electrophoresis 
(Methods 11). In the first dimension a pH gradient 
of 3.5 - 9 was employed and in the second dimension 
the SDS polyacrylamide gel contained 10% acrylamide. 
The protein on the gel was transferred to nitro­
cellulose by electrophoresis (Methods 12.1) and 
probed with an antibody against the DNase (Methods
12.3). The blot was then dried and subjected to 
autoradiography at -80°C.
Marker lane: Myosin 205kDa, Galac tosidase 116kDa,
Phosphorylase b 97.4kDa, BSA 66kDa, Egg albumin 
45kDa, Carbonic anhydrase 29kDa.
a = autoradiography 
b = immunoblot
9__________________ D IM E N S IO N __________3.5-
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4. Phosphopeptide analysis of DNase phosphorylated 
in vitro & in vivo
DNase phosphory lated jln vitro (Methods 16) or i j i  vivo 
(Methods 17) was subjected to one dimensional polyacrylamide 
gel electrophoresis (Methods 9) and transferred to a PVDF 
membrane (Methods 16). After autoradiography the DNase 
region was cut from the membrane and the protein digested 
with tpck-treated trypsin. The digest was then subjected 
to chromatography on a Pharmacia FPLC system (Methods 16). 
The resultant phosphopeptide FPLC profiles are shown in 
Figures 4.1 & 4.2.
The cAMP protein kinase produced one labelled peak 
which eluted at fraction 25, protein kinase C produced 
two labelled peaks which eluted at fractions 11 & 16, and 
casein kinase II and the US3 protein kinase both produced 
two labelled peaks which co-eluted at fractions 10 & 15.
The FPLC profile of the cell culture labelled
DNase (Figure 4.2) showed no recognisable peaks and when 
compared to the i.n vitro profiles (Figure 4.3) none of 
the peaks present in those profiles could be aligned 
with it. The problem was that not enough [ ] was
incorporated into the DNase during the labelling 
experiment.
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Figure 4,1 F.P.L.C. analysis of the tryptic 
digests of in_ vitro phosphorylated DNase.
DNase purified from cells infected for 18 hrs. 
(Methods 2.2, 6.1) was incubated with cAMP dep. 
protein kinase (Materials), protein kinase C 
(Methods 6.2.1), casein kinase II (Methods 
6.2.3) or the US3 protein kinase (Methods 6.2.2) 
in the presence of ^ [ ^ ^ J A T P  (Methods 16).
The samples were then acetone precipitated 
(Methods 8.1) and subjected to electrophoresis 
on an SDS polyacrylamide gel, 3 mm. thick 
containing 10% acrylamide (Methods 9). The 
proteins were then transferred to a PVDF 
membrane (Methods 16) by electrophoresis.
The membrane was subjected to autoradiography 
and the DNase band cut out and digested with 
tpck-treated trypsin (Methods 16). The digest 
was then subjected to chromatography on a Mono 
Q column on a Pharmacia FPLC system using a 
0-1M KC1 gradient in 20mMTris-HClpH7.5 (Methods 
16).
Cherenkov activity of the fractions was then 
measured in a scintillation counter.
159
2-00
*o
oo
zom
z
H3J
§
O
z
o
c
s
03
m
13
ZO l>3JH2m0200 -OTs
ro
o
cn
roo
coo
o ooo
>
C/3
m
£
z
>
CO
m
K )
iTJO
oTJ
s
H
31
§
o
z
T|
33
>
O
HI
I  i
oo Z
z czo )=,m «c
m
33
o
cn
o
cn
roo
coo
co L 
<*0 oooo
" 0
3 3
O
— I
m
>co
m
O
ZO l>3JHZmOZOO —OTs
160
2UO
o"U
2
+
7sO
O
Oz
o
mzH3J
§
oz
m
33
>
O
H
O
Z
m
33
o
cn
_JLo
cn
iocn
coo
co L 
<*0 o ooo
O>
Q.
CD
TD
■
“0
XIo
H
m
Z O  !>33HZmOZOO -OTs
>
(/)
m
2 -DO
7's O
O
oz
om
zH
7J
5
oz
*n
33
>
O
H
m
33
o
cn
o
cn
tocn
coo
co L 
°>o o ooo
u
£  31
m  ^
z A
g C / )
CD CO
m
Z O  l>33HZmOZOO - O  7s
161
120 1.2
100
80 0.8
C
P
M
60 0.6
40 0.4
20 0.2
60 10 15 20 25 30 35
C
0 
N 
C 
E 
N 
T 
R 
A 
T
1
O
N
M
FRACTION NUMBER
CPM + -  KCI CONCENTRATION
Figure 4.2 F.P.L.C. analysis of the tryptic digest
o n
of cell culture [ ] labelled DNase. DNase was purified
from cells infected for 12 - 15 hrs. (Methods 2.2, 6.1) 
and which had been labelled with 2 - 3mCi [ ^ p] for 11 - 
14 hrs. (Methods 17). The purified DNase was then acetone 
precipitated (Methods 8.1) and subjected to electrophoresis 
on a 10% acrylamide SDS gel. The protein was then trans­
ferred to PVDF membrane by electrophoresis (Methods 17).
The membrane was then stained with Coomassie blue (Methods
10.1), destained in 50% methanol and the DNase band cut 
out and digested overnight with tpck-treated trypsin 
(Methods 17). The digest was then subjected to chroma­
tography on a Mono Q column on a Pharmacia FPLC system 
using a 0-1MKC1 gradient in 20mMTris-HCl pH 7,5 (Methods 17). 
The radioactivity of each sample was measured in the presence 
of scintillant in a scintillation counter.
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Figure 4.3 Comparison of the FPLC phosphopeptide 
profiles produced from jLn vitro phosphorylated DNase & 
(Figure 4.1) cell culture [ ^ P ]  labelled DNase 
(Figure 4.2).
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5. Studies of the endonuclease activity of the DNase
The DNase enzyme has an endonuclease activity (Hoffman 
& Cheng 1979, Hoffman P. 1981) as well as the exonuclease 
activity which was used to monitor its purification (Methods
5.1, 6.1). A plasmid G35a (Methods Figure 18.1) containing 
a restriction fragment from the HSV-1 genome was used as 
a substrate. The inserted fragment contains the cleavage 
site for the production of unit genomic lengths from 
concatenated viral DNA (see Introduction 1.2).
The plasmid was used to see if the endonuclease activity 
of the DNase could act in a site specific manner under 
conditions where only this activity was active.
5.1 The effect of pH on endonuclease activity
The assays were set up as described in Methods 18.4 
except that the activity of the enzyme was tested in a 
series of buffers at pH’s 5.5, 6.0, 6.5, 7.0, 8.0 & 9.0.
The samples used were DNase purified from 18 hr. infected 
cell lysates (Methods 2.2,,6.1), the 10K spin supernatant 
from 18 hr. infected cell lysates (Methods 2.2) and a 
mixture of both. The samples were incubated at 37°C for 
5 mins. and then subjected to electrophoresis on agarose 
gels (Methods 18.2).
The purified DNase alone had no effect on the plasmid 
(Figure 5.1.1) at any pH. The infected supernatant 
digested the plasmid at all p H ’s, it degraded the covalently 
closed circular form to mainly the open circular form with 
some linear forms produced at p H ’s 5.5 to 7.0. At pH's 
8.0 and 9.0 it degraded the plasmid equally to the open 
circular form and linear form. The mixture of the purified 
DNase and infected supernatant also degraded the plasmid, 
it degraded the closed circular from to the open circular 
and linear forms at all pH's.
165
5.2 The effect of time on the endonuclease activity
The assays were set up as described in Methods 18.4.
The Effect of time I
The samples used were DNase purified from 18 hr. 
infected cells (Methods 2.2, 6.1), the 10K spin supernatant 
from 18 hr. infected cells (Methods 2.2) and a mixture of 
both. Assays were incubated for 5, 30 or 60 mins. at 37°C 
and then subj ected to electrophoresis on agarose gels 
(Methods 18.2). The purified DNase had no effect on the 
plasmid under the conditions employed (Figure 5.2.1), 
the infected supernatant had completely digested the plasmid 
by 5 mins. of incubation. The purified DNase and infected 
supernatant mixture had digested the plasmid to the open 
circular and linear forms by 5 mins. and had completely 
digested the plasmid by 30 mins. .
The Effect of time II
In this experiment the sample used was DNase purified 
from 18 hr. infected cells (Methods 2.2, 6.1). The assays 
were incubated for 1, 5, 10, 20, 30 or 60 mins. at 37°C 
and the DNA was ethanol precipitated (Methods 18.1). The 
DNA was then digested with the restriction enzyme Hind III 
(Methods 18.3) and the samples subjected to electrophoresis 
on agarose gels (Methods 18.2). At each time point employed 
only the linearized plasmid form was found (Figure 5.2.2) 
which indicated that the DNase had not digested the plasmid 
in any way.
5.3 The endonuclease activity of partially purified DNase
The assays were set us as described in Methods 18.4.
The samples used were those collected during the purification 
of the DNase from 18 hr. infected cell lysates (Methods 2.2>
6.1) and used to determine the purification data (Results 
Table 1.1). The samples were the infected cell homogenate, 
10K spin infected supernatant, the DNase pool from DE52 
Cellulose chromatography, the DNase pool from Phosphocellulose 
chromatography and the Aquacide concentrated DNase pool from 
DNA Cellulose chromatography. The assays were incubated
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for 5 rains, at 37°C and then subjected to electrophoresis 
on agarose gels (Methods 18.2). The infected cell homogenate 
completely digested the plasmid (Figure 5.3.1) as did the 
10K spin supernatant except for a faint band of linearized 
plasmid. The DNase pool from DE52 Cellulose chromatography 
completely digested the plasmid to the linear form whilst 
the DNase pool from phosphocellulose chromatography digested 
the plasmid to the open circular form with only limited 
linear production. The purified DNase (the concentrated 
DNase pool from DNA Cellulose chromatography) had no effect 
on the plasmid under the conditions employed.
5.4 The effect of uninfected cell supernatant on the
endonuclease activity
The assays were set up as described in Methods 18.4 
except that poly (dl.dC).poly (dl.dC) was included in the 
assays in order to prevent non-specific binding to the 
plasmid. The samples used were DNase purified from 
18 hr. infected cell lysates (Methods 6.1), the 10K spin 
supernatant from uninfected cells (Methods 2.2 except 
uninfected cells used) and a mixture of the above. The 
assays were incubated at 37°C for 5 mins. and then subjected 
to electrophoresis on agarose gels (Methods 18.2). The 
purified DNase had no effect on the plasmid (Figure 5.4.1), 
the uninfected supernatant had completely digested the 
plasmid by 5 mins.. The mixture digested the plasmid to 
the open circular and linear forms.
5.5 Double digestion of the plasmid to determine site
specificity
The duplicate assays were set up as described in 
Methods 18.4 except that poly (dl.dC).poly (dl.dC) was 
added to prevent non-specific binding. The samples 
used were a mixture of DNase purified from 18 hr. 
infected cell lysates (Methods 6.1) and uninfected 10K 
spin supernatant (Methods 2.2 except uninfected cells 
used) or infected 10K spin supernatant from 18 hr. cell 
lysates (Methods 2.2). The assays were incubated for
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2 mins. at 37°C then the DNA was ethanol precipitated 
(Methods 18.1). The DNA was then digested with the 
restriction enzymes Hind III or Pst I (Methods 18.3) and 
the samples subjected to electrophoresis on agarose gels 
(Methods 18.2). The only distinct bands produced by the 
digestions were those of linearized plasmid (Figure 5.5.1). 
These would result from the action of the restriction 
enzymes on covalently closed or circular forms of the 
plasmid.
5 .6 The effect of dephosphorylation of the DNase 
on its endonuclease activity
The assays were set up as described in Methods 18.4.
The samples used were DNase purified from 18 hr. infected 
cell lysates (Methods 6.1) which had been treated by the 
protein phosphatases 1 (PP1) or 2A (PP2A) (Methods 13.4) 
and the protein phosphatases themselves.
The assays were incubated at 37°C for 2 mins. and then 
subjected to electrophoresis on agarose gels (Methods 18.2).
The purified DNase which had been treated with the 
phosphatases digested the plasmid (Figure 5.6.1). The 
DNase treated with PP1 digested the plasmid to the open 
circular and linear forms whilst that treated with PP2A 
digested the plasmid almost completely to the linear form.
The samples treated with phosphatase alone gave similar 
digestion patters (Figure 5.6.2). Phosphatase 1 and PP1 
treated DNase digested the plasmid to the open circular 
and linear forms and the pattern obtained was identical.
PP2A treated DNase digested the plasmid to the open circular 
and linear forms with the linear form dominating. The
phosphatase 2A completely digested the plasmid.
When the digestions were carried out in the presence 
or absence of 20mM pyrophosphate, a phosphatase inhibitor, 
it was observed that where the pyrophosphate was present 
no digestion of the plasmid occurred (Figure 5.6.3). In 
the absence of the pyrophosphate, the phosphatases and
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the phosphatase treated DNase samples all digested the 
plasmid. In the case of the PP1 samples mainly the 
open circular form resulted with some linears and for 
the PP2A samples mainly linear forms resulted.
16$
pH 6.5
a » »  - ■ »
Figure 5.1.1 The effect of pH on the ability of DNase 
to digest plasmid G35a. The endonuclease activity of 
DNase purified from cells infected for 18 hrs. (Methods
2.2, 6.1) was tested over a range of pH 5.5, 6.0, 6.5,
7.0, 8.0 & 9.0, the 10K spin infected supernatant from
cells infected for 18 hrs. (Methods 2.2) and a mixture 
of both were also tested. The conditions chosen allowed 
only the DNase’s endonuclease function to be active. The 
samples were incubated at 37°C for 5 mins. and then sub­
jected to electrophoresis on a 1% agarose gel at 100V 
for 2 hrs.
Key 0 = original plasmid
1 = purified DNase
2 = infected supernatant
3 = mixture of 1 & 2
CCC = covalently closed circular plasmid
0C = open circular plasmid
L = linear plasmid
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Figure 5.2.1 The effect of time on the endo­
nuclease activity of DNase purified from cells 
infected for 18 hrs. (Methods 2.2, 6.1),the 10K 
spin supernatant from cells infected for 18 hrs. 
(Methods 2.2) and a mixture of both. The conditions 
chosen allowed only the DNaseTs endonuclease function 
to be active. The samples were incubated at 37°C 
for 5, 30 or 60 mins. and then subjected to electro­
phoresis on a 1% agarose gel for 2 hrs. at 80V.
Key 0 = original plasmid
E = EcORI digest of the plasmid 
1 = 5  mins. digestion
2 = 30 mins. digestion
3 = 60 mins. digestion 
I.S.= Infected Supernatant
Figure 5.2.2 The effect of time on the endo­
nuclease activity of DNase purified from cells
infected for 18 hrs. (Methods 2.2, 6.1). The
conditions chosen allowed only the DNase's endo­
nuclease function to be active. The samples were 
incubated for 1 , 5, 10, 20, 30 or 60 mins. at 37°C, 
then ethanol precipitated (Methods 18.1) and digest­
ed for hrs. at 37°C with Hind III. The samples 
were then subjected to electrophoresis on a 1% 
agarose gel at 100V. for 2 hrs..
Key 0 = original plasmid
1,5,10,20,30,60 = time of DNase digestion 
markers
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Figure 5.3.1 The endonuclease activity of partially 
purified DNase fractions obtained during the purification 
of DNase from cells infected for 18 hrs. (Methods 2.2, 
6.1). The conditions chosen allowed only the DNase's 
endonuclease function to beartive. The samples were 
incubated at 37°C for 5 mins. and then subjected to 
electrophoresis on a 1% agarose gel for 2 hrs. at 100V..
Key 0 = original plasmid
E = EcORl digest of the plasmid
dD = EcORl | Hind III double digest of the plasmid
H3 = Hind III digest of the plasmid
H = Cell homogenate
S = 10K spin supernatant
DE = DE52 Cellulose DNase pool
PC = Phosphocellulose DNase pool
DC = DNA Cellulose DNase pool = purified DNase
OC = open circular plasmid
L = linear plasmid
CCC = covalently closed plasmid
Figure 5.4.1 The effect of uninfected supernatant on 
the endonuclease activity. DNase purified from cells 
infected for 18 hrs. (Methods 2.2, 6.1), 10K spin super­
natant from uninfected cells (Methods 2.2) and a mixture 
of both were assayed in conditions where only the DNase 
endonuclease function was active. The samples were 
incubated at 37°C for 5 mins. and then subjected to 
electrophoresis on a 1% agarose gel at 80V. for 2 hrs.
Key 0 = original plasmid 
D = purified DNase 
US = uninfected supernatant 
M = mixture of D & US
OC = open circular plasmid 
L = linear plasmid
CCC = covalently closed circular plasmid
1/A
(1 H 1 2 1 2 P 0
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Figure 5.5.1 Double digestions of the plasmid.
DNase purified from 18 hr. infected cells (Methods 
2.2, 6.1) together with either 10K spin supernatant 
purified from 18 hr. infected cells (Methods 2.2) or 
10K spin supernatant purified from uninfected cells 
(Methods 2.2 uninfected cells) was incubated with the 
plasmid for 2 mins. at 37°C. The conditions chosen 
allowed only the DNasefs exonuclease function to be 
active. The DNA was then ethanol precipitated (Methods 
18.1) and digested with either Hind III or PstI for 
hrs. at 37°C. The samples were then subjected to electro­
phoresis on a 1% agarose gel at 100V. for 2 hrs..
Key 0 = original plasmid
H = Hind III digestion of the plasmid 
P = Pstl digestion of the plasmid 
IS = DNase + infected supernatant 
US = DNase + uninfected supernatant
1 = 2nd digestion with Hind III
2 = 2nd digestion with Pstl
OC = open circular plasmid 
L = linear plasmid
CCC = covalently closed circular plasmid
Figure 5.6.1 The effect of dephosphorylation on 
endonuclease activity. DNase purified from cells 
infected for 18 hrs. (Methods 2.2, 6.1) was treated 
with either protein phosphatase 1 or 2A (Methods
13.4) and then its endonuclease activity was assay­
ed. The conditions chosen allowed only the DNase's 
endonuclease activity to be active. The samples 
were incubated for 2 mins. at 37°C and then sub­
jected to electrophoresis on a 1% agarose gel for 
2 h r s . at 100V..
Key 0 = original plasmid
H = Hind III digestion of the plasmid 
PI = PP1 treated DNase 
P2 = PP2A treated DNase 
D = Untreated DNase
oc = Open circular plasmid 
1 = linear plasmid
ccc = covalently closed circular plasmid
Figure 5.6.2 The effect of protein phosphatases 
on endonuclease activity. DNase purified from 
cells infected for 18hrs. (Methods 2.2, 6.1) and 
treated with either protein phosphatase 1 or 2A 
(Methods 13.4) was assayed for endonuclease activity 
as were the protein phosphatases. The conditions 
chosen allowed only the DNase's endonuclease function 
to be active. The assays were incubated at 37°C 
for 2 mins. and then subjected to electrophoresis 
on a 1% agarose gel at 80V. for 2 hrs.
Key 0 = original plasmid
ID = PP1 treated DNase 
2D = PP2A treated DNase 
IP = PP1 
2P = PP2A
F i guns 56.1.
o o c l c l  n
F igure 5.6.2.
Figure 5.6.3 The effect of phosphatase inhibitors on 
the endonuclease activity. DNase purified from cells 
infected for 18 hrs. (Methods 2.2, 6.1) and treated with 
protein phosphatase 1 or 2A (Methods 13.4) and the phos­
phatases themselves were assayed for endonuclease activity 
in the presence or absence of 20mM pyrophosphate, a phos­
phatase inhibitor. The conditions chosen allowed only 
the DNase’s endonuclease function to be active. The 
samples were incubated at 37°C for 2 mins. and then sub­
jected to electrophoresis on a 1% agarose gel at 9 0 V . 
for 2 hrs..
Key 0 = original plasmid
+ = 20mM pyrophosphate present 
- = no inhibitor present 
PI = PP1 
P2 = PP2A
P1D = PP1 treated DNase 
P2D = PP2A treated DNase
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6. Xanthate studies
The virally coded US3 protein kinase and other 
cellular protein kinases were partially purified to 
examine what effect the xanthates D609, D611 endo and 
D611exo, known antiviral agents (Sauer G. et al 1984, 
Amtmann E. et al 1987, MUller-Decker K. et al 1987), 
would have on their i_n vitro activities.
6 .1 Kinase purification
The protamine kinase profile from the DE52 cellulose
column (Methods 19.1) shown in Figure 6.1.1 gave the
position of the US3 protein kinase which eluted at
200mMKCl. Further specific kinase assays (Methods 5.2)
determined the positions of the cellular kinases. The
fractions used for the inhibitor studies were:
US3 protein kinase fraction 37, protein kinase C fraction
2+
16, cAMP dep. protein kinase fraction 11, Ca /Calmodulin 
dep. protein kinase fraction 36, casein kinase I fraction 
16 and casein kinase II fraction 38.
6.2 Inhibitor studies
Xanthate concentrations in the ^>M range had no 
significant effect on the activity of the US3 protein 
kinase (Figure 6.2.1) but an increase into the mM 
concentration range resulted in up to 90% inhibition 
of the kinase (Figure 6.2.2). The xanthate D609 was 
found tohave the greatest inhibitory activity which 
was reflected in its value of 5mM (Table 6.2.1),
compared to values of 15mM and 18mM for the xanthate 
isomers D611 exo and D611 endo respectively.
This was found to be repeated throughout the 
inhibitor studies (Figures 6.2.3 - 6.2.7; Table 6.2.1). 
The xanthate D609 had the greatest inhibitory activity 
with ICtjQ values of 4 - 5mM. The isomers D611 exo and 
D611 endo had a lesser inhibitory activity with IC^q 
values at least double that of the corresponding D609 
value.
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The only exception to this was in the case of cAMP dep. 
protein kinase where the values for all three
xanthate compounds were in the range 4 - 7mM.
Lmcweaver - Burk analysis of the inhibition of US3 
protein kinase by the xanthates relative to the ATP 
concentration was carried out. In the case of D609 
(Figure 6.2.8), Vmax remained unchanged at each xanthate 
concentration showing that the inhibition was competitive 
in nature. A Dixon .plot of ^v against [i] for the D609 
(Figure 6.2.9) compound gave a value for its Ki of 850pM.
Ki is the dissociation constant for the enzyme: inhibitor 
complex and can be used as a measure of the relative 
activity of inhibitors.
In the case of the two D611 isomers, D611 exo 
(Figure 6.2.10) and D611 endo (Figure 6.2.12) a similar 
analysis suggests that they too function as competitive 
inhibitors. Dixon plots of the two isomers (Figures 
6.2.11 & 6.2.13) gave Ki values of 2.5mM for D611 exo 
& 2mM for D611 endo. These values agree with the 
ICt-Q values (Table 6.2.1) which showed the D609 compound 
to be the best inhibitor of kinase activity.
6.3 The effect of the xanthate D609 on the DNase in 
cell culture
A 15 hr. HSV-l(F) infection (Methods 2.2) was 
carried out in the presence of 20yg/ml xanthate D609 
and 10|jg/ml undecanoic acid. The resultant 10K spin 
supernatant (Methods 2.2) was acetone precipitated 
(Methods 8.1) and subjected to electrophoresis on a 
two dimensional polyacrylamide gel system (Methods 11).
The first dimension used a pH gradient of 3.5 - 9 and 
the second dimension an SDS polyacrylamide gel containing 
10% acrylamide. The gel was transferred to nitrocellulose 
and probed with an antibody against the DNase (Methods 12).
When compared to the control, the blot of the DNase 
prepared in the presence of the xanthate (Figure 6.3.1) 
showed a shift in the distribution of the spots. More 
protein appeared to be concentrated in the spots at more
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basic pi values and less protein was present in the 
spots at the more acidic pi values. This suggested 
that the xanthate had prevented the modification of 
the DNase.
Quantitative analysis of the two profiles by 
laser densitometry (LKB Ultroscan XL) confirmed the 
qualitative analysis above (Table 6.3.1).
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Figure 6.1.1 Protamine kinase activity (Methods 5.2) 
of an HSV-l(F) infected cell lysate prepared from cells 
infected for 18 hrs. (Methods 19.1) and subjected to 
chromatography on DE52 Cellulose (Methods 19.1).
Elution was carried out with a linear gradient of 
0 - 0.5M KC1 in DE Buffer (Materials 2.3).
Key • - ■ Kinase activity +  KC1 concentration
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Figure 6.2.1 The effect of the xanthates D609, 
D611exo and D611endo at y M  concentrations on the 
activity of the US3 protein kinase (fraction 37 
Figure 6.1.1) using protamine as a substrate 
(Methods 5.2, 19.2).
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Figure 6.2.2 The effect of the xanthates D609, 
D611 exo & D611 endo at mM concentrations on the 
activity of the US3 protein kinase (fraction 37 
Figure 6.1.1) using protamine as a substrate 
(Methods 5.2, 19.2).
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Figure 6.2.3 The effect of the xanthates D609, 
D611 exo and D611 endo at mM concentrations on 
the activity of protein kinase C (fraction 16 
Figure 6.1.1) using histone Ills as a substrate 
(Methods 5.2, 19.2).
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Figure 6.2.4 The effect of the xanthates D609, 
D611 exo and D611 endo at mM concentrations on 
the activity of cAMP dependent protein kinase 
(fraction 11, Figure 6.1.1) using histone H A S  
as a substrate (Methods 5.2, 19.2).
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Figure 6.2.5 The effect of the xanthates D609,
D611 exo and D611 endo at mM concentrations on
2+the activity of Ca : calmodulin dependent 
protein kinase (Fraction 36, Figure 6.1.1) using 
myosin as a substrate (Methods 5.2, 19.2).
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Figure 6.2.6 The effect of the xanthates D609, 
D611 exo and D611 endo at mM concentrations on 
the activity of casein kinase I (fraction 16, 
Figure 6.1.1) using casein as a substrate 
(Methods 5.2, 19.2).
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Figure 6.2.7 The effect of xanthates D609 , D611 
exo and D611 endo at mM concentrations on the 
activity of casein kinase II (fraction 38, Figure 
6.1.1) using casein as a substrate (Methods
5.2, 19.2).
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Table 6,2,1 The inhibitory effect of the xanthates 
D609 , D611exo & D611endo on the HSV-1 
viral kinase & cellular kinases
KINASE IC50 * (mM)
D609 D611exo D611endo
US3 protein kinase 5 15 18
Protein kinase C 5 12 12
cAMP dep protein kinase 4 5 7
2Ca :Calmodulin dep protein kinase 4 18 20
CKI 4 8 10
CKII 5 12 13
* ICtjQ is the concentration of xanthate required to 
inhibit kinase activity by 50%
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Figure 6.2.8 Lineweaver-Burk analysis of the 
effect of the xanthate D609 on the US3 protein 
kinase (fraction 37, Figure 6.1.1) activity 
relative to the ATP concentration (Methods
5.2, 19.2).
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Figure 6.2.9 Dixon analysis of the effect 
of the xanthate D609 on the US3 protein kinase 
(fraction 37, Figure 6.1.1) activity relative 
to the ATP concentration (Methods 5.2, 19.2).
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Figure 6.2.10 Lineweaver-Burk analysis of the 
effect of the xanthate D611 exo on the US3 
protein kinase activity (fraction 37, Figure
6.1.1) relative to the ATP concentration 
(Methods 5.2, 19.2).
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Figure 6.2.11 Dixon analysis of the 
effect of the xanthate D611 exo on the US3 
protein kinase (fraction 37, Figure 6.1.1) 
activity relative to the ATP concentration 
(Methods 5.2, 19.2).
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Figure 6.2.12 Lineweaver-Burk analysis of 
the effect of the xanthate D611 endo on the 
US3 protein kinase (fraction 37, Figure
6.1.1) activity relative to the ATP concent­
ration (Methods 5.2, 19.2).
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Figure 6.2.13 Dixon analysis of the effect 
of the xanthate D611 endo on the US3 protein
kinase (fraction 37, Figure 6.1.1) activity
relative to the ATP concentration (Methods
5.2, 19.2).
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Figure 6.3.1 The effects of the xanthate D609 
in cell culture.
A 15 hr. HSV-l(F) infection (Methods 2.2) was 
carried out in the present of 20pg/ml. D609 and 
lOyg/ml. undecanoic acid. The resultant 10K 
spin supernatant was acetone precipitated 
(Methods 8.1) and subjected to electrophoresis 
on a two dimensional polyacrylamide gel system 
(Methods 11).
The first dimension used a pH gradient of 3.5 - 
9 and the second dimension an SDS polyacrylamide 
gel containing 10% acrylamide. The proteins 
were transferred to nitrocellulose by electro­
phoresis (Methods 12.1) and probed with an anti­
body against the DNase (Methods 12.3). A 
marker lane was run at the side of the second 
dimension and was visualised by Ponceau S 
staining (Methods 12.2).
Marker lane: Myosin 205kDa, ^>Galactosidase
116kDa, Phosphorylase b 97.4kDa, BSA 66kDa,
Egg albumin 45kDa, Carbonic anhydrase 29kDa.
a = control 
b = + xanthate
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Table 6.3.1 Quantitative analysis of DNase purified
from 15 hr. infected BHK cells in the 
presence or absence of xanthate D609 by 
laser densitometry
% area of each region in the large 
spot at more acidic pi values
3 . 5 + <------------------------ -~10
Profile 1 2 3
15 hr. DNase 33% 38% 29%
15 hr. DNase + Xanthate 12% 40% 48%
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Figure 6.3.2
Quantitative analysis of DNase purified 
from 15 hr. infected BHK cells in the 
presence or absence of xanthate D609 
by laser densitometry
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7. Ribonucleotide reductase : 2 dimensional gel
analysis of the large subunit
A two dimensional polyacrylamide gel analysis 
(Methods 11) of ribonucleotide reductase was carried 
out at various times after infection (Methods 2.2) 
using acetone precipitates (Methods 8.1) of the 
infected cell supernatants.
Immunoblotting of these gels (Method 12) resulted 
in the profiles shown in Figure 7.1.
The profiles for the 3, 6 & 9 hr. large subunit 
contained an elongated spot which appeared to be made 
up of at least three identifiable sub-regions. The 
12, 15 & 18 hr. large subunit profiles had a similar 
pattern present in each. The profile was made up 
of two spots, the spot at more basic pi values being 
the larger and darker of the two. The spot at more 
acidic pi values was more pronounced in the 12 hr. 
profile and in the 15 & 18 hr. profiles became much 
fainter. The molecular weight of the reductase large 
subunit on polyacrylamide gels is 140kDa, the molecular 
weight of the species observed in these experiments was 
60kDa. Intact large subunit was seen on blots of one 
dimensional polyacrylamide gels (Figure 7.2) but the 
intact subunit could not be observed on blots of two 
dimensional gels under any of the conditions employed 
in this study.
The 60kDa species was found in all the time course 
blots and so allowed comparisons to be made between them. 
The nature of the modification of the intact subunit 
remains unclear, but it is known to be phosphorylated 
in cell culture (Preston V. et al 1984).
Quantitative analysis of the profiles by laser 
densitometry (LKB Ultroscan XL) confirmed the qualitative
analysis given above (Table 7.1). The analysis showed a 
reduction in modification between 9 hr. & 12 hr..
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Figure 7.1.1 Iramunoblots of two dimension poly­
acrylamide gels of the large subunit of ribo­
nucleotide reductase at 3, 6, 9, 12, 15 & 18 hrs. 
after infection. Acetone precipitates (Methods
8.1) of infected cell supernatants (Methods 2.2) 
were subjected to electrophoresis. In the first 
dimension a pH gradient of 3.5 - 9 was employed 
and in the second dimension the SDS polyacrylamide 
gel contained 10% acrylamide (Methods 11). The 
protein in the gels was transferred to nitro­
cellulose by electrophoresis (Methods 12.1) and 
probed with an antibody against the large sub­
unit (Methods 12.4). A marker lane was run at 
the side of second dimension and visualised by 
Ponceau S Staining (Methods 12.2).
Marker lane: Myosin 205kDa, ^>Galactosidase
116kDa, Phosphorylase b 97.4kDa, BSA 66kDa,
Egg albumin 45kDa, Carbonic anhydrase 29kDa.
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Figure 7.2 The Immunoblot of a one dimensional 
polyacrylamide gel of the large subunit of ribonucleotide 
reductase. The 10K spin supernatant from cells infected 
with HSV-1 for 6 hrs. (Methods 2.2) was subjected to 
electrophoresis on an SDS polyacrylamide gel containing 
10% acrylamide (Methods 9). The gel was transferred to 
Nitrocellulose and probed with an antibody against the 
reductase large subunit (Methods 12). A marker lane 
was run and was visualized by Ponceau S staining (Methods 
12.2) .
Marker lane Myosin 205kDa, ^Galactosidase 116kDa, 
Phosphorylase b 97.4kDa, BSA 66kDa, Egg Albumin 45kDa, 
Carbonic anhydrase 29kDa.
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Table 7.1 Quantitative analysis of ribonucleotide
reductase large subunit time course profiles 
by laser densitometry
% area of 
3 5 + <
each region 
spot
of the
'rof ile 1 2 3
3 h r . 11% 44.4% 44.4%
6 h r . 20% 38% 42%
9 h r . 18% 47% 35%
12 hr . 29% 71%
15 h r . 20% 80%
18 hr. 11% 89%
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Figure 7.3
Quantitative analysis of ribonucleotide 
reductase large subunit time course 
profiles by laser densitometry
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1. The Viral Deoxyribonuclease
1.1 The two dimensional profile of the DNase
The viral DNase purified from HSV-1 infected BHK 
cells was shown, by two dimensional polyacrylamide gel 
analysis and immunoblotting to be highly modified (Results 
Section 2). The antibody used was (Ql) a gift from Dr.
K. Powell and is a monoclonal which reacts against a 
site-common epitope on HSV-2 and HSV-1 DNase. The Ql 
monoclonal has been shown to be specific for the DNase 
by Banks et al (1983 & 1985) and binding of the monoclonal 
inhibits the exonuclease activity of the enzyme.
Enzyme activity was present at 3 hr. post infection
but no signal was obtained after two dimensional gel analysis
and immunoblotting. Banks et al (1985) using immunofluor- 
esence showed that the DNase in HSV-1 infected cells was 
just starting to be synthesised at 3 hr. p.i.. It is 
probable that there was not enough DNase protein after 
purification, to produce a signal with the antibody after 
immunoblotting. At 6 hr. p.i. and throughout the rest of 
the infection the majority of the DNase appeared highly 
modified. The highly modified DNase profiles contained 
discrete spots which varied in their respective proportions 
(Results Figure 2.1.1 and Table 2.1) during the infection 
as judged by laser densitometry. The variation in the 
relative proportions of the large highly modified region 
of the DNase suggested the return to less modified forms 
of the enzyme at late times in infection. This may reflect 
a less stringent requirement for the degree of modification 
of the enzyme by the virus at these times or the fact that 
at these late times in the infection the ATP reserves of 
the host cell may be depleted and so the modification cannot 
be maintained. The reason for the presence of the two 
regions of less modified DNase (Results Figure 2.1.1) at 
some times (9, 15 & 18 hr. p.i.) and not others is unclear.
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As stated above towards late times in infection the enzyme 
may not be required by the virus and so the presence of 
these less modified DNase species occurs because the enzyme 
is less stringently controlled. At earlier times the less 
modified species of the enzyme may be required by the virus 
for a particular function. Modification then alters the 
enzyme structure and function and allows it to play another 
role in the viral infection.
1.2 Phosphorylation of the DNase
The modification of the enzyme has been shown to be 
due in part to phosphorylation (Results Section 3 & 4).
Banks et al (1985) showed using the Ql monoclonal that 
DNase purified from [ ^ P ]  labelled cells infected with 
HSV-2 was a phosphoprotein. In this study we have taken 
this further to investigate which kinases are responsible 
for the phosphorylation of the enzyme.
Labelling of HSV-1 infected BHK cells in culture 
with inorganic phosphate has shown the DNase to
incorporate the isotope by 6 hr. p.i. (Results Figure
3.2.1). In in. vitro studies the purified DNase can be 
utilised as a substrate by the cellular kinases: protein 
kinase C, cAMP dependent protein kinase and casein kinase 
II and by the HSV-1 encoded US3 protein kinase (Results 
Section 3). Purified DNase was also a substrate for 
protein phosphatase 1 as judged by the altered 2 dimensional 
gel profile obtained after incubation of the DNase with this 
enzyme, indicating the removal of phosphate from the nuclease.
Tryptic peptide analysis of jLn vitro phosphorylated 
DNase resulted in the production of two unique profiles, 
for cAMP dependent protein kinase and protein kinase C, 
and two profiles which had identical peaks, the US3 protein 
kinase and casein kinase 2, (Results Figure 4.1).
This finding maybe the result of an incomplete 
digestion of the PVDF bound DNase by tpck-treated trypsin.
This would release large peptides which may contain 
phosphorylation sites for both the US3 protein kinase and 
casein kinase 2, and result in the identical pattern
observed. On the other hand the result may also be due
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to similar or identical phosphorylation sites on the 
DNase for the two kinases, which on trypsin digestion 
would result in identical phosphopeptide profiles.
The cell culture [ ^ p ] labelled DNase phospho­
peptide profile contained no defined peaks, which is
o O n
a direct result of not having enough [ p] incorporated
into the DNase. This is due to the fact that the
labelling process is inefficient and only a small
proportion of the label added to the medium ends up
in the cells. Subsequently very little label is 
incorporated into the protein of interest. This could 
be overcome to some extent by increasing the amount of 
label used in the experiment, but this introduces problems 
in handling the labelled material, disposing of contaminated 
waste materials and the health and safety regulations.
Comparisons between in vitro and cell culture 
phosphopeptides failed to resolve which kinases are 
responsible for the phosphorylation of the DNase in 
cell culture, (Results Fig. 4.1, 4.2 & 4.3).
However, the xanthate studies (See Discussion 
Section 3) suggested that protein kinase C (or a 
kinase activated by protein kinase C) was responsible, 
in part, for the phosphorylation of the DNase in cell 
culture.
The effect of phosphorylation on the function of the 
DNase is not known, as the function of the enzyme in the 
viral infection still remains unclear. Preston & Cordingley 
(1982) expressed the DNase in Xenopus oocytes using viral 
DNA or mRNA and showed after expression the presence of a 
new exonuclease activity. They did not check to see if 
the newly synthesised protein contained phosphate. However 
if phosphorylation is required by the DNase for exonuclease 
activity kinases homologous to those operative in natural 
infection must be present in the Xenopus oocyte and cellular 
in nature.
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Phosphorylation may not be required for the exonuclease 
function but for the endonuclease function of the enzyme 
though no cellular or viral deoxyribonuclease has been 
reported to be regulated by phosphorylation. This may 
be a result of the lack of research into the regulation 
and study of deoxyribonucleases in general. A possible 
role for phosphorylation in the regulation of the enzyme 
is in the mediation of its interactions with other viral 
or cellular proteins. The DNase is known to interact with 
the viral major DNA binding protein (Vaughan et al 1984) 
which stabilises the enzyme in infected cells. Phosphory­
lation of the DNase may be a requirement for this interaction, 
or others. It maybe these proteins which in turn modify 
the activity of the DNase.
Examples where phosphorylation affects the interaction 
of two proteins include the p85 subunit of the phosphatidyl 
inositol 3 kinase (PI 3 kinase), which phosphorylates the 
inositol ring of phosphatidyl inositol at position 3. p85
mediates the binding of the PI3 kinase to the ligand activated 
tyrosine autophosphorylated PDGF receptor kinase domain, 
binding does not occur when the receptor is not activated 
and the kinase domain is not auto-tyrosine-phosphorylated 
(Escobedo et al 1991, Ostu et al 1991).
Another example is in the product of the retino­
blastoma gene pBR, which plays a crucial role in the 
regulation of normal cell growth. Loss or alteration of 
this gene can lead to cell transformation. pBR is phos- 
phorylated in a cell-cycle dependent manner by the cdc2 
kinase (Cooper & Whyte 1989, Taya et al 1989), with 
phosphate first detected on entry to the Sphase and 
lost on emergence from the Mphase. Hyperphosphorylation 
of the pBR protein is thought to be a regulatory event 
which leads to the inactivation of its growth repressing 
functions. The hyperphosphorylated pBR is easily extracted 
from nuclei but the un- or underphosphorylated pBR species 
are tightly associated with the nuclear structure (Mittnacht 
& Weinberg 1991). The underphosphorylated species of pBR
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has been found associated with the E2F transcription factor 
and an inhibitor of E2F, E2F-I (Chellappan et al 1991, Bagchi 
et al 1991).
The transcription factor AP-1, inducible by phorbol- 
esters, consists a heterodimer of the products of the cellular 
oncogenes fos and ,jun. API is modulated by an inhibitory 
protein IP1, which specifically blocks the DNA binding of 
API. Phosphorylation of IP-1 prevents or disrupts its 
association with AP-1 thus allowing it to bind to TPA 
responsive elements in the DNA (Auwerx & Sassone-Corsi 1991).
Phosphorylation may be sequential with phosphorylation 
at one site allowing the phosphorylation of another site and 
the kinase involved using the initial phosphate group as a 
site determinant such as glycogen synthase kinase 3 (Kemp 
& Pearson 1990) which requires a phospho serine group four 
amino acids C terminal of its target serine.
Other HSV-1 viral proteins that are phosphorylated 
and have known functions include the immediate-early protein 
c*4 (Ackermann et al 1989) and the ribonucleotide reductase 
(Preston et al 1984) . It is still unclear what role phos­
phorylation plays in the function or control of these proteins. 
In the field of virology, in general, phosphorylation of viral 
proteins and the role of this modification in their function 
or control is not well understood, (for a review see Leader 
& Katan 1988). One of the best studied examples is the NS 
protein of the enveloped RNA virus, vesicular stomatitis virus 
(VSV). The NS protein is required by the virus for secondary 
transcription. The protein is found in two forms, one 
of which is highly phosphorylated and one of which has a 
low state of phosphorylation. In in_ vitro transcription 
assays only the highly phosphorylated NS protein enhanced 
viral transcription (Kingsford & Emerson 1980) and this 
activity could be abolished by dephosphorylation (Hsu et 
al 1982). The phosphorylation of the NS protein maybe 
due in part to the cellular protein kinase C (Mllller Decker 
et al 1987) .
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The studies carried out in this Thesis used BHK cells 
in culture as the host for HSV-1 infection but it must be 
remembered that these cells are fibroblastic in origin and 
have been adapted to grow in cell culture. It is probable 
that protein kinases are present in BHK cells which are not 
present in the cells infected in the animal host. The 
cells infected in the animal host are differentiated and 
have stopped dividing. The protein kinases present in 
dividing BHK cells may phosphorylate the DNase in a fortuitous 
manner which has no effect on its function. The virally 
coded US3 protein kinase, which may phosphorylate the DNase 
in cell culture, is not required for virus growth in cell 
culture (Purves et al 1987a) and so presumably has a cellular 
equivalent which can substitute for its role in viral infect­
ion. This cellular homologue may affect the phosphorylation 
of the DNase. The US3 protein kinase is similar to the 
ribonucleotide reductase and thymidine kinase which are also 
not required for growth in cell culture (See Introduction 
Section 2.2) but may well be required in the animal host 
for infection in cells which are terminally differentiated 
and so do not contain the enzymes required for DNA metabolism.
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1.3 ADP ribosylation of the DNase
The other type of modification which may be present 
on the DNase is mono- or poly ADP ribosylation. Treatment 
of the purified DNase with snake venom phosphodiesterase, 
an exonuclease which cleaves -XpYpZ to -XpY+pZ, resulted 
in the production of two regions, on the 2D gel profile 
which we were unable to relate to those seen in the time 
course immunoblots. The fact that the 2D gel profile 
was altered suggested that the DNase had contained ADP 
ribose or poly (ADP ribose).
ADP ribosylation (for review see Ueda & Hayaishi 
1985) is a type of covalent modification which involves 
the transfer of ADP ribose from NAD+ to an amino acid 
on a receptor protein (Fig. 1.1). There are two types 
of this modification, mono ADP ribosylation (e.g. the 
bacterial toxins cholera and diptheria) and poly ADP 
ribosylation (e.g. eukaroytic chromatin bound poly (ADP 
ribose) polymerase). Poly ADP ribosylation has been 
implicated in NAD metabolism,cell differentiation and 
RNA metabolism. It has also been shown to be involved 
in the repair of DNA strand breaks, and in cell death 
when DNA damage has become extensive (Gaal & Pearson 1985, 
Berger 1985, Gaal et al 1987, Denhardt & Kowalski 1988).
In the context of viral infections the best known example 
of ADP ribosylation is during the infection of E .coli by 
bacteriophage T4. When phage T4 infects E.coli it utilises 
the host RNA polymerase to transcribe its own genes. In 
order to enable the E.coli RNA polymerase to carry this 
out the enzyme is specifically modified by ADP ribosylation 
(Cohen 1983). In the case of HSV-1, the immediate- 
early protein c*4 has been ADP ribosylated jin vitro (Preston 
& Natarianni 1983) but the protein has not been shown to 
be modified in vivo
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The function of the modification of the DNase, if 
confirmed, is unclear but it may be involved in the inter­
action of the protein with viral DNA or with viral (or 
cellular) proteins. It must be noted that ADP ribosylation 
activity is higher in dividing cells and the modification 
maybe the consequence of the cell culture system used rather 
than a necessary modification.
1.4 Comments
The role of covalent modification in the function 
and/or control of the HSV-1 DNase is unclear, though this 
may also be due to the fact that the function of the enzyme 
in viral infection is still unknown, and so we lack a 
specific assay for its function. The use of an expression 
system which could produce completely unmodified DNase would 
be a useful tool in the further study of this enzyme. This 
would allow the effect of the covalent modifications to be 
judged separately or in conjunction, on firstly its known 
in vitro functions and then in time on its in vivo functions.
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2. The endonuclease activity of the HSV-1 deoxyribonuclease
The virally coded deoxyribonuclease maybe essential 
for virus growth and production in cell culture systems 
(Moss 1986) but not viral DNA synthesis (Weller et al 1990). 
The enzyme is highly modified and its function in the viral 
infection which makes it essential is unclear. The exo- 
nucleolytic function of the enzyme seems an unlikely candidate 
for this essential function. Its endonucleolytic function, 
seems a more likely candidate, although it is not sequence 
specific. It may be involved in the cleavage of concatenated 
viral DNA which also does not appear to be sequence specific 
but occurs at a certain distance from each of the recognition 
sites (Varmuza & Smiley 1985) (cf EcoK, EcoB type 1 restrict­
ion enzymes from E.coli which cleave dsDNA at a site l-5kb 
from their recognition sequences).
Chou & Roizman (1989) showed that the DNase could 
bind to sequences in the ’a ’ region containing P a d  and 
Pac2, the cleavage and packaging signals (See Introduction
1.2 and 3.2). The DNase also bound to other sequences 
but the binding appeared to be less strong. The cleavage 
of concatenated viral DNA occurs in the DR1 sequence between 
two adjacent ’a ’ sequences (Varmuza & Smiley 1985). The 
plasmid used in our studies (Methods Fig. 18.1) contained 
two adjacent ’a ’ sequences, derived from the junction 
between UL and U s> in the vector pUc9.
Under the conditions used the purified DNase itself 
had no endonuclease activity against the plasmid as judged 
by agarose gel electrophoresis. This result disagrees 
with all the published data (Hoffman & Cheng 1979, Hoffman 
1981, Strobel-Fidler & Francke 1980 & Banks et al 1983).
These groups obtained endonuclease activity from their 
purified preparations. The purification procedures in 
all cases differed as did the purity of each group’s final 
preparations, Hoffman & Cheng (1978) did not show a gel 
of their purified enzyme, Strobel-Fidler & Francke’s (1980) 
preparation contained at least three other proteins, Banks 
et a l ’s (1983) final preparation contained one protein but 
used a different assay to determine endonuclease activity.
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The enzyme preparations used in this study were active 
exonucleolytically and the conditions used for the 
endonuclease assay were those of Hoffman (1981). The 
reason for the lack of endonuclease activity remains unclear.
The addition of infected supernatant to DNase in the
assay produced a digestion pattern on agarose gels which
was distinct from that of the infected supernatant alone.
A similar result was obtained using uninfected supernatant,
which suggested the DNase had in some way protected the
plasmid by either binding to it itself or binding the
protein(s) in the supernatants responsible for the digestion.
Digestions carried out with the DNase in the presence of
infected or uninfected supernatants showed no evidence of
specific cleavage of the plasmid. These experiments were
difficult to resolve because of the presence of other exo-
2+nucleolytic activities at 5mM Mn
The fractions obtained during the purification of 
the DNase all had endonucleolytic activity up to the 
DNA cellulose purified DNase which did not. This suggested 
that either the endonuclease activity seen in the above 
assays was a distinct protein which did not purify with 
the DNase on DNA cellulose chromatography or that the DNase 
required a protein cofactor(s) for the cleavage of the 
plasmid (no evidence for specific cleavage) and this protein 
was lost on the DNA cellulose chromatography step.
Treatment of the DNase by either protein phosphatase 
1 or protein phosphatase 2A had no effect on its endo­
nuclease activity. It must be noted that treatment of 
the DNase with protein phosphatase 1 (Results Figure 2.5.1) 
did not result in a complete reduction in the modification 
of the enzyme. It is impossible to say if the remaining 
modification was due solely to the possible poly ADP ribose 
' or to it and residual phosphate moieties. As stated in 
Section 1 the phosphorylation of the DNase may not affect 
its activity directly but rather its interactions with 
other proteins which indirectly modulate its activity.
The surprising result was the digestion of the plasmid 
by the protein phosphatases themselves. Since the
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digestion of the plasmid was inhibited by 20mM pyro­
phosphate, a protein phosphatase inhibitor, we can 
attribute this property to the phosphatases rather than 
to an unknown protein in their preparations.
The role of this endo/exo nuclease activity, if 
confirmed, in the protein phosphatases jln vivo functions 
is unclear.
The assay used in these experiments permitted the 
study of endonuclease activity of simple systems such 
as the purified DNase itself but problems occurred when 
trying to study its possible iji vivo role of cleaving 
concatenated viral DNA. Encapsidation of and cleavage 
to unit lengths of viral DNA are linked together and 
require specific proteins some of which may not have 
been identified. This leads to problems in the assay 
system: 1) which proteins are required for cleavage
and can these be purified and added back to the assay,
2) can an extract from virus infected cells substitute, 
which may contain all the proteins required, but also 
some which may interfere with the assay.
3. Xanthate studies
The studies of Mliller-Decker et al (1987) on the 
effect of the antiviral xanthate D609 in cell culture 
indicated a role as possible protein kinase inhibitors 
(Introduction Section 6). This possibility was investigated 
using partially purified protein kinases from HSV-1 infected 
BHK cells. The results from the inhibitor studies (Results 
Section 5) showed that the xanthates, D609, D611 exo and 
D611 endo (Introduction Figure 6.2), could inhibit all the 
protein kinases used in the study in a non-specific manner. 
The xanthate D609 had the greatest inhibitory activity with 
an average value of 4.5 (lo.5)mM, the two isomers
D611 exo & D611 endo had values more than double this at
11.7(+4•3)mM and 13.3(+4,4)mM respectively. The xanthates 
acted as competitive inhibitors with respect to ATP.
However, the concentrations at which they inhibited the 
protein kinases did not correlate with the concentrations
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at which they act as antiviral agents in cell culture 
which were in t h e p M  range. The difference makes it 
highly unlikely that they act as protein kinases inhibitors 
in cell culture at jj M concentrations.
MUller-Decker et al (1988) indicated a possible role 
for the xanthate D609 as an inhibitor of phospholipase C 
and so as an indirect inhibitor of protein kinase C.
2+Protein kinase C is activated by diacylglycerol (& Ca ions) 
which is produced by the action of phospholiphase C on 
phosphatidyl inositol in the cell membrane. It has been 
shown recently that the activiation of phospholipase C ^
(one of the four isozymes of the enzyme) is achieved by 
the phosphorylation of specific tyrosine residues by the 
platlet derived growth factor (PDGF) receptor kinase (cf 
EGF receptor kinase Introduction Section 5.1.1) (Kim et 
al 1991). It has not yet been determined whether the 
xanthate inhibits the activation of the phospholipase C 
or inhibits the enzyme directly.
The cell culture experiment using the xanthate D609 
showed that at 15 hr. p.i. the two dimensional gel profile 
of the DNase after immunoblotting was altered. The change 
in profile was confirmed by laser densitometry (Results 
Figure 6.3.1 & Table 6.3.1). This provides evidence that 
protein kinase C or a protein kinase activated by protein 
kinase C is responsible for some of the phosphorylation 
of the DNase. If however, phosphorylation is sequential 
and certain protein kinases require a protein kinase C 
phosphorylated residue on the enzyme as a site determinant, 
as discussed in Section 1.2, then this would also lead to 
the reduced modification seen in Figure 6.3.1.
The antiviral activity of the xanthates against a 
wide range of viruses (Sauer et al 1984) suggests a role 
for protein kinase C in the infectious cycle of these 
viruses, e.g. phosphorylation of the VSV NS protein 
(MUller-Decker et al 1987). Other groups have also 
reported evidence which implies a role for protein kinase 
C in viral infections, these include HIV (Kinter et al 1990), 
Influenza Type A virus (Kurokawa et al 1990) and Polyomavirus 
(Asano et al 1990).
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The inhibition of the activation of protein kinase C 
by xanthates provides an antiviral agent with a wide­
spread range (Saner et al 1984), as long as protein 
kinase C is essential for the virus life cycle then the 
xanthates will have an antiviral effect. Problems, 
however, arise in the nature of the interaction between 
the xanthate and its inhibition of phospholipase C.
If the interaction is specific to virally infected cells 
then the xanthates constitute a new group of antiviral 
agents with great potential. If the inhibition, however, 
is non-specific and occurs in other cells, as has been 
shown (MUller-Decker et al 1988), then problems will 
arise in cells which require to activate protein kinase 
C via. phospholipase C in response to certain growth 
factors such as PDGF. So far no studies on the toxic 
effects on whole animals, if any, have been reported.
4. Ribonucleotide reductase
The virally coded ribonucleotide reductase, which 
produces deoxyribonucleotides from ribonucleotides, is 
not required for virus growth in cell culture (See Intro­
duction 2.2) but is probably required for the virus’ 
infectious cycle in its host animal cells. The ribonucleotide 
reductase function is located in the C terminal domain of 
the large subunit and the whole of the small subunit. The 
N terminal domain of the large subunit contains a protein 
kinase activity which autophosphorylates and phosphorylates 
exogeneous substrates. The N terminal domain of the HSV-1 
reductase large subunit is highly susceptible to proteolysis 
in vivo and many related species of lesser molecular weight 
than the large subunit are found. Some of these species 
are enzymatically active in the ribonucleotide reductase 
function. The HSV-2 large subunit protein kinase domain 
has been implicated in the ability of the virus to transform 
certain cells. It is possible that degradation of the 
HSV-1 large subunit protein kinase domain prevents trans­
formation in cells which contain the necessary proteases.
The function of the N terminal protein kinase domains and 
their substrates, (although the small subunit of the enzyme 
has been suggested as a possibility) remains unclear, but
242
the enzyme is known to be phosphorylated in cell culture.
The results of the two dimensional gel electro­
phoresis and immunoblotting with an antibody raised against 
the C terminus of the large subunit of HSV-1 ribonucleotide 
reductase (Results Section 7) are difficult to analyse.
They contain only a 60kDa C terminal fragment of the 140kDa 
protein. They clearly showed that the C terminal fragment 
was modified at early times, in the infection, and that 
this modification was maintained up to 9 hr. p.i.. The 
immunoblots showed the presence of three species of the 
C terminal fragment. Between 9 and 12 hr. p.i. the 
modification was reduced to two species, the species at 
more acidic pi values decreased from 12 to 18 hr. p.i. 
where it was barely visible. These results provided an 
inconclusive view of the large subunits modification because 
they lack the N terminal domain and its modification, if 
any. We can speculate that the decrease in modification, 
probably phosphorylation though this requires confirmation, 
between 9 and 12 hr. p.i. may indicate that the reductase 
function is no longer required by the virus and so its 
modification does not need to be maintained.
This assumes that the modification is required for 
reductase activity which has not yet been demonstrated. 
Another possibility is that the decrease in modification 
between 9 and 12 hr, p.i. may indicate a switch from 
the reductase function to the protein kinase function of 
the N terminal domain. The third possibility is that 
modification Somehow affects the interaction of the two 
subunits and a decrease in modification may cause 
dissociation of the enzyme.
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